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Abstract 
Infection with Vibrio cholerae 01 causes dehydrating diarrhea, although it is now treatable 
disease with low case-fatality in settings with appropriate medical care. However, cholera 
continues to impose considerable mortality in the world ' s most impoverished populations. 
Natural infections usually give medium range immunity and it has been hypothesized that 
the protective immunity to V cholerae infection may be mediated by anamnestic memory 
B-cell responses. An oral cholera vaccine, Dukoral is a killed inactivated vaccine which 
provides protection against the disease through the development of antigen specific memory 
B-cells. This study was carried out to compare memory B-cells and serological responses in 
Bangladeshi healthy young children (2-5 years, n=20), older children (6-17 years, n=20) and 
adults (18-45 years, n=32) after oral cholera vaccination. These responses to cholera 
antigens including lipopolysaccharide (LPS) and cholera toxin B subunit (CtxB) were 
assessed prior to immunization (day 0) and then on different study days using polyclonal 
stimulation of peripheral blood mononuclear cells (PBMC) followed by an enzyme linked 
immuno spot assay (ELISPOT) procedure. Adult vaccinees developed cholera toxin CT -
specific IgA and IgG memory B cell responses by day 30 which remained detectable 
through at least for 90 days. In case of both younger and older child vaccinees, there was no 
significant level of CT -specific IgG memory B-cell responses, but the responses tended to 
be higher at day 30 (P=0.0625) post immunization. However, there was no significant 
elevation of the magnitude of LPS-specific IgA or IgG memory B-cell responses in any age 
group of vaccinees. Plasma antibody responses were measured by using the enzyme linked 
immunosorbant assay (ELISA) procedure. Adult vaccinees developed plasma CT-specific 
IgA and IgG for a longer duration of 3 months and 6 months, respectively, whereas these 
responses were relatively short-lived for the child vaccinees. The response to vaccination 
was also assessed by using the vibriocidal antibody assay. It was found that adult vaccinees 
developed high vibriocidal responses throughout the study period of 6 months, whereas 
these responses persisted for one month in both groups of child vaccinees. These results 
suggest that adult vacinees confer relatively long-term protection after oral cholera 
vaccination compared to young and older child vaccinees. 
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CHAPTER ONE 
INTRODUCTION 
1. Background 
Diarrheal diseases caused by enteric pathogens remain a leading global health problem. 
Almost half of all cases of diarrhea is due to bacteria that cause disease by producing one or 
more enterotoxins [1]. Vibrio cholerae is an important cause of diarrheal morbidity and 
mortality. The vast majority of human disease is attributed to V. cholerae serogroups 01 and 
0139, both of which are noninvasive pathogens that colonize the small intestine and cause 
secretory diarrhea[2]. In countries such as Bangladesh, cholera is endemic and both the rural 
and urban population is afllicted with biannual outbreaks[3] with an approximate incidence 
of 200 cases/IOO,OOO individuals per year, where the majority of fatal cases occur in young 
children [4-5]. In addition to endemic outbreaks, sporadic outbreaks can occur whenever 
sanitation and clean water provisions are lacking, as evidenced by the outbreak beginning in 
2008 in Zimbabwe that affected over 100,000 individuals and resulted in more than 4,000 
deaths [6] as well as outbreaks in 2010 in Pakistan and Haiti [7] following the collapse of 
infrastructure [8]. 
However, infection with V. cholerae induces protective immunity lasting from 3-7 years and 
the majority of patients with cholera develop robust humoral and mucosal Immune 
responses [9]. Volunteer and epidemiologic studies demonstrate that clinically apparent 
infection with V. cholerae confers long-term protection of at least 3 years against subsequent 
disease [10-11]. The best-studied marker of protective immunity is the vibriocidal antibody, 
a complement-dependent bactericidal antibody; however, there is no vibriocidal antibody 
titer at which complete protection is achieved [12]. Furthermore, the vibriocidaI response 
wanes rapidly, and it is hypothesized that the vibriocidal antibody may reflect other longer 
lasting, protective immune responses occurring at the mucosal surface[l3]. 
Patients with cholera develop additional humoral immune responses to several antigens 
including cholera toxin subunit B (CTB), toxin-coregulated pilus major subunit A (TcpA), 
and LPS [14]. It has been shown that serum anti-CTB immunoglobulin A (IgA) antibody 
levels are also associated with protective immunity independent of the vibriocidal antibody 
on exposure to cholera, but serum IgA levels also wane rapidly after infection [15]. 
Although levels of serum anti-LPS and anti-CTB IgG antibodies increase considerably after 
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infection, these have not been shown to correlate with protection from V. cholerae infection 
in humans [16]. 
With the recognition of the fact that safe water and improved hygiene will not be immediate 
realities to those most affected by cholera, the World Health Organization recently issued an 
updated position statement on the role that cholera vaccines should play in limiting the 
cholera disease burden [17]. It has recently been shown that vaccinees developed immune 
responses that were generally comparable to those in individuals recovering from natural 
disease [18]. 
Currently, two oral cholera vaccines are licensed and available: a killed V. cholerae 01 
vaccine supplemented with recombinant nontoxic cholera toxin B subunit (CtxB; WC-rBS; 
Dukoral; Crucell) and a bivalent killed V. cholerae 0 I/O 139 vaccine not containing 
supplemental CtxB (0110139 WC; Shanchol-India, ORC-VAX-Viet Nam) [6, 19-20]. Both 
types of vaccines are safe and immunogenic and are usually administered in two doses 
separated by I to 6 week [21-22]. 0 I/O 139 WC provided approximately 70% protection in a 
recent field study in Kolkata [23] and is currently being evaluated in a larger field trial in 
Bangladesh. The WC rBS vaccine provides 85 to 90"10 protective efficacy against cholera in 
few months following a two-dose regimen [24], but this efficacy falls toward baseline within 
24 to 36 months of vaccination, especially in children who may not have had previous 
exposure like the adults [5]. In comparison, natural cholera induces protection that lasts for 
years or decades after infection [11]. 
Vaccine studies performed in areas in which cholera is endemic showed, older children and 
adults more-robust in immune responses which may have been primed by prior exposure to 
V. cholerae 01. Memory B cells (MBCs) are generated after natural infection and response 
upon antigenic exposure [25]. It has previously been demonstrated the presence of memory 
B cell responses in adults with cholera in Bangladesh [26] and that children are able to 
mount significant antibody responses to V. cholerae antigens following both natural 
infection and vaccination [5]. The aim of the present study was to characterize the B-cell 
immune response to oral cholera vaccine in children compared to those in adults. 
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1.1 Global epidemiology of cholera 
Cholera has been endemic in southern Asia since recorded history. Cholera has spread 
globally in seven pandemic waves since 1817, of which the current one began in 1961. In 
2008, the WHO reported 190,130 cholera cases worldwide, associated with 5143 deaths 
(98% in Africa), but cholera is globally under-reported and the true disease burden is 
estimated to be in the million [8, 27]. Cholera is a disease that occurs in low-income regions 
of the world where sanitation and food and water hygiene are inadequate. lmported cases 
occasionally occur in travelers returning from endemic areas. In areas without clean water or 
sewage disposal (as may occur after natural disasters or in displaced populations in areas of 
conflict), cholera can spread quickly and has a case fatality rate of as high as 50"10 in 
vulnerable groups with limited medical care [28]. The World Health Organization (WHO) 
reports the emergence of new, apparently more virulent, strains of V. cholerae 01 is now 
predominant in parts of Africa and Asia, and the emergence and spread of antibiotic resistant 
strains. 
Cholera often occurs in large epidemics or pandemics. In the 19th century pandemics 
frequently originated from the Ganges delta in India, and up to the mid 20th century, were 
largely confined to Asia (except for a large epidemic in Egypt in 1947). The current, seventh 
pandemic caused by V. cholerae 01 EI Tor originated in Indonesia in 1961 and spread 
rapidly through most of Asia. In 1970, this biotype was introduced into West Africa, and is 
now endemic in many African countries. In 1991 , it was introduced into Peru where it had 
been absent for nearly 100 years, and from there spread throughout many countries of Latin 
America. Another serogroup, V. cholerae 0139, was discovered as the cause of cholera 
epidemics in India and Bangladesh in 1992 and has since spread to other countries in South 
East Asia. Apart from a few imported cases, this serogroup is not known to have occurred 
outside Asia [28]. 
Annual global figures (2009) reported by WHO include 221 ,226 cases and 4,946 deaths 
from 45 countries. The majority of cases (98%) were reported from Africa where an 
outbreak, that started in 2008 and lasted for almost a year, spread to South Africa and 
Zambia. By the end of July 2009, over 98,000 cases and 4,000 deaths were reported in this 
outbreak. Asia reported an 82% decrease in cases in 2009 compared to 2008, however, 
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reports of acute watery diarrhea, many of which may be cholera, were not included. Recent 
cholera epidemics include the 2008-2009 epidemic in Zimbabwe and the 2010 epidemic 
following the January earthquake in Haiti [7, 29]. The V. cholerae strain responsible for the 
Haiti epidemic is nearly identical to the EI Tor 01 strains predominant in southeast Asia; the 
ancestry is distinct from that of circulating Latin American and East African strains of V. 
cholerae. suggesting introduction of the strain from Asia [30]. 
1.2 Epidemiology of cholera in Bangladesh 
Cholera is endemic in Bangladesh, and outbreaks occur in a regular seasonal pattern. A 
systematic surveillance for cholera has been carried out in Bangladesh by the International 
Centre for Diarrheal Disease Research (icddr, b) for more than 35 years [31-32]. A number 
of studies have shown that epidemic outbreaks in Bangladesh usually occur twice during a 
year, with the largest number of cases occurring during September to December, just after 
the monsoon [33-34]. A somewhat smaller peak of cholera cases is also observed in the 
spring between March and May. 
Until 1970, more than 90% of cholera in Bangladesh was caused by the classical lnaba 
serotype; by 1972, 85% of all cases were due to the classical Ogawa serotype [35]. The El 
Tor biotype of V. cholerae 01 appeared in Bangladesh in 1969/1973 and since this biotype 
had completely replaced the classical biotype. However, in 1982, the classical biotype 
reemerged as the predominant epidemic biotype in Bangladesh [36] and coexisted with the 
EI Tor vibrios until 1992. Data obtained from studies of diarrhea epidemics in nearly 400 
rural subdistricts by ICDDR,B medical teams between 1985 and 1991 showed that V. 
cholera 01 was the most frequently (40"10) isolated enteropathogen during the epidemics 
[32]. The 1991 epidemic was estimated to have caused between 210,000 and 235,000 cases 
and over 8,000 deaths [32]. During 1992 and 1993, an epidemic of severe and deadly watery 
diarrhea caused by V. cholerae 0139 occurred in southern Bangladesh and later spread to 
the other parts of the country including Dhaka [37-38]. In 1992, there were approximately 
220,000 cases of cholera caused by serotype 0139 within a 12-week period, with over 8,000 
deaths that was more deaths than in all of Latin America that same year [39]. 
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1.3 Risk for travelers 
The overall risk of cholera for travelers is extremely low and is in the order of 0.2 cases per 
100,000 travelers [40-41]' For long-term travelers in areas of outbreaks the rate may be as 
high as 500 cases per 100,000 travelers [40], and when routine screening for V. cholerae is 
done in travelers with diarrhea who have returned from endemic areas, the rate may 
approach five cases per 100,000 [42]. Activities that may predispose to infection include 
drinking untreated water or eating poorly cooked seafood in endemic areas. Travelers living 
in unsanitary conditions, for example relief workers in disaster or refugee areas, are also at 
risk. 
2. Vibrio choleare: The causative agent of cholera 
In 1883 Robert Koch demonstrated that cholera is produced by a bacterium that he referred 
to as 'comma(-shaped) bacteria' [43], later designated V. cholerae. V. cholerae, a member of 
the family Vibrionaceae, is a facultatively anaerobic, Gram-negative, non-spore-forming 
curved rod, about I.4-2.6/-lm long, capable of respiratory and fermentative metabolism; it is 
well defined on the basis of biochemical tests and DNA homology studies. The bacterium is 
oxidase-positive, reduces nitrate, and is motile by means of a single, sheathed, polar 
flagellum. 
Figure 1.1: Vibrio cholerae 
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2.1 Classification 
Antigenic variation plays an important role in the epidemiology and virulence of cholera. 
Differences in the sugar composition of the heat-stable surface somatic "0 " antigen are the 
basis of the serological classification of V. cholerae first described by Gardner & 
Venkatraman [44]; currently the organism is classified into 206 "0 " serogroups . Until 
recently, epidemic cholera was exclusively associated with V. cholerae strains of the 0 I 
serogroup. 
Vibrio cholera 
1 
CT Producing 
0139 
Classical & El Tor 
~ I Non-CT Producing I 
Non-Ol , Non-0139 
[> 95% strains are 
I Non-Epidemic I 
Figure 1.2: The current classification scheme of epidemic and non-epidemic strains of V. 
cholerae. Serogrouping is based on the 0 antigenic polysaccharide moiety ofO-PS ofLPS. 
All epidemics V. cholerae 01 /0139 strains are CT producer. 
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All strains that were identified as V. cholerae on the basis of biochemical tests but that did 
not agglutinate with "0" antiserum were collectively referred to as non-O I V. cholerae. The 
non-O I strains are occasionally isolated from cases of diarrhea [45] and from a variety of 
extraintestinal infections, from wounds, and from the ear, sputum, urine, and cerebrospinal 
fluid [46]. They are ubiquitous in estuarine environments, and infections due to these strains 
are commonly of environmental origin [47]. The 01 serogroup exists as two biotypes, 
classical and EI Tor; antigenic factors allow further differentiation into two major serotypes-
Ogawa and lnaba. Strains of the Ogawa serotype are said to express the A and B antigens 
and a small amount of C antigen, whereas Inaba strains express only the A and C antigens. 
A third serotype (Hikojima) expresses all three antigens but is rare and unstable. 
The simple distinction between V. cholerae 0 I and V. cholerae non-O I became obsolete in 
early 1993 with the first reports of a new epidemic of severe, cholera-like disease in 
Bangladesh [37] and India (Ramamurthy et a\. , 1993b). At first, the responsible organism 
was referred to as non-O I V. cholerae because it did not agglutinate with 0 I antiserum. 
However, further investigations revealed that the organism did not belong to any of the 0 
serogroups previously described for V. cholerae but to a new serogroup, which was given 
the designation 0139 Bengal after the area where the strains were first isolated. Since 
recognition of the 0139 serogroup, the designation non-Ol non-0139 V. cholerae has been 
used to include all the other recognized serogroups of V. cholerae except 0 I and 0139. 
2.2 Cholera Toxin: The virulence factor causing secretory diarrhea 
The pathogenesis of cholera is a complex process and involves a number of factors which 
help the pathogen to reach and colonize the epithelium of the small intestine and produce the 
enterotoxin that disrupts ion transport by intestinal epithelial cells. The existence of cholera 
enterotoxin (CT) was first suggested by Robert Koch in 1884 and demonstrated 75 years 
later by [48] and Dutta, Pause & Kulkarni (1959) working independently. Subsequent 
purification and structural analysis of the toxin showed it to consist of Al and A2 subunit and 
5 smaHer identical B subunits [49]. The A subunit possesses a specific enzymatic function 
and acts intracellularly, raising the cellular level of cAMP and thereby changing the net 
absorptive tendency of the small intestine to one of net secretion. The crucial role of CT in 
disease was clearly shown by Levine et al. [50], who fed purified CT to volunteers. 
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Ingestion of 25 Jig of pure CT (administered with cimetidine and NaHC03 to diminish 
gastric acidity) caused over 20 liters of rice water stool, and ingestion of as little as 5 Jig of 
pure CT resulted in I to 6 liters of diarrhea in five of six volunteers. 
2.2.1 The mechanism of action of the cholera toxin 
Infection normally starts with the oral ingestion of food or water contaminated with V. 
cholerae. In human volunteer studies, the infectious dose was determined to be fairly high, 
and varied depending on the inocula conditions (ranging from 106 to 10" colony-forming 
units). This high dose is probably needed because of the acid sensitivity of V. cholerae cells, 
which are exposed to low pH in the gastric compartment [51]. The surviving bacteria adhere 
to and colonize the intestinal epithelial cells, eventually producing the CT and causing 
cholera symptoms [52]. The B subunit is responsible for specific binding to the GMI 
ganglioside receptor of epithelial cells [53-54] 
Upon binding, the A subunit is translocated into the host cell cytosol, where it is activated 
by thiol dependent reduction, probably by thiol: protein disulfide oxidoreductases [55]. Only 
the resulting nicked AI subunit possesses an ADP-ribosylating activity that targets the host 
cell G-protein Gsa. ADP ribosylated Gsa in tum permanently activates adenyl ate cyclase 
activity, leading to increased levels of intracellular cAMP. cAMP inhibits active sodium 
chloride absorption and increases chloride and bicarbonate secretion [56]. This results in 
passive water loss, leading to a marked decrease in intravascular volume, hypotension and 
hypoperfusion of critical organs and in severe cases death ensues with a high mortality rate. 
81 Page 
v. chdeTae Grolera toxin 
~~-- A1 
No+ I lnlestilal krnen I 
H2O 
(I) 1 (a) GM1g1yroproiein Hero- (b) H2O K+ .--....... / 'eceplo< ~I ran. 
~ oororrfl!fllll!llfjJ~ 
I Erterocy" I 
No+ 
i I 
ATP 
oo~ 
Adenyla" 
cyclase 
lnaciv. 
Ame 
Figure 1.3: The mechanism of action of the cholera toxin. (a) The CT molecule binds to 
GMI in the apical membrane of the gut epithelial cell . (b) The molecule is internalized in an 
endosome. (c) The Al (enzyme) subunit is released, and catalyses the transfer of ADPribose 
from NAD to u subunit of a G protein. (d) The G protein can no longer act to switch off 
adenyl ate cyclase, and the cyclic AMP level in the cell rises (e). This increase in cAMP 
causes ion channels in tbe apical membrane to open, allowing ions to escape from tbe cell 
(t). 
(http://accessmedicine. net/loadB inary. aspx?name=ryan5&fi lename=ryan5 _ c03 2 m02t .gi t) 
2.3 Lipopolysaccbaride 
The lipopolysaccharide (LPS) of V. cholerae represents the most abundant of exposed 
molecules in the outer membrane of Gram-negative bacteria, and contributes to barrier 
function [57-58]. It is considered one of the most important antigens from the point of view 
of immunogenicity in these bacteria [59] Toxicity is associated with the lipid component 
(Lipid A) and immunogenicity is associated witb tbe polysaccharide components although 
both act as determinants of virulence. During infection, V. cholerae cells are exposed to a 
series of changes, such as temperature, acidity, osmolarity and exposure to antibacterial 
agents and innate immune system components. 
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The cell wall antigens (0 antigens) of gram-negative bacteria are components of LPS. 
Somatic (0) antigen or 0 polysaccharide is attached to the core polysaccharide. The 
individual chains vary in length ranging up to 40 repeat units. (Fig: 1.3) A major antigenic 
determinant (antibody-combining site) of the gram-negative cell wall resides in the 0 
polysaccharide [60). 
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Figure 1.4: General architecture of Lipopolysaccharide in gram negative bacteria 
(http://pathmicro.med.sc.edulfoxllps.jpg) 
3. Cholera toxin: A paradigm of a multifunctional protein 
CT is not just another enterotoxin that causes the signs and symptoms of the dreaded 
disease, cholera. It is unique in many respects, starting from its structure to its functions. CT 
is a multifunctional protein that is capable of influencing the immune system in many ways. 
It not only has remarkable adjuvant properties, but also has its role in mucosal tolerization 
and vaccine development. 
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3.1 Adjuvant activity of cholera toxin 
That CT possessed adjuvant activity, that was first reported in the early seventies [59]. The 
adjuvant activity of CT may be attributed to the enhanced antigen presentation by various 
types of antigen presenting cells (APCs), such as macTophages, dendritic cells (DCs) and B 
cells. In B cells, both recombinant CT (rCT) and recombinant CTB (rCTB) promote isotype 
differentiation that leads to increased IgA formation. It has been suggested that both 
enzymatic activity and receptor binding contribute to the stimulatory effects of the toxin 
[61]. CT has also been reported to upregulate various cell surface molecules such as co-
stimulatory molecules and chemokine receptors in murine and human DCs as well as in 
other APCs [62-63]. CT also stimulates the secretion of IL-l from macrophages, which 
enhances their APC function [64]. 
3.2 Cholera toxin B subunit for mucosal tolerization and immunotherapy 
Mucosal tolerance is a mechanism whereby the immune system, upon encounter with 
harmless antigens through a mucosal surface, develops means to avoid reacting III a 
deleterious manner to tbe same antigen even if the antigen is encountered by a systemic 
route. A significant improvement has been acbieved by co-administering CTB as an 
immuno-modulating agent to enhance the tolerogenic activity of autoantigens as well as 
allergens given orally or nasally. The use of antigen coupled to CTB has been found to 
minimize by several hundred-fold the amount of antigenltolerogen needed and also to 
reduce the number of doses tbat would otherwise be required by reported protocols of 
tolerance induction by tbe oral route [65]. More importantly, at divergence from the use of 
free antigen, CTB-linked antigens have been shown to work also in an already sensitized 
individual. As recently reviewed [66], in experimental systems this has also resulted in 
effective suppression of various pathological immune responses associated with 
experimental autoimmune diseases, type r allergies and allograft rejection when the CTB-
antigen conjugate was administered as therapy ratber than for prevention. 
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3.3 The CTB antigen in the whole cell oral cholera vaccine 
The toxicity of CT has precluded its use for human vaccination. Instead, nontoxic B subunit 
of CT, the CTB component has been extensively used without any side effects as a mucosal 
immunogen in humans. Indeed, recombinantly produced CTB is an important component of 
an oral cholera vaccine for human use. In addition to CTB, this vaccine also contains 
inactivated whole-cell cholera vibrios and is being registered (Dukoral) in more than 60 
countries worldwide. The vaccine has proved to be safe and efficiently immunogenic in both 
adults and children. When given orally in two or three doses, the vaccine has been found to 
stimulate the same levels of intestinal IgA antitoxin and antibacterial (mainly anti-
lipopolysaccharide) antibodies as seen in convalescence from severe form of clinical 
cholera. The vaccine has also been found to induce very long-lasting (more than 2 years) 
immunologic memory in the intestinal mucosa. 
4. Treatment 
4.1 Hygienic and Sanitary Control 
Prevention is always better than cure. To prevent cholera some measures are recommended 
as follows-
• Bottled water (intact seal) or tubewell water/tap water that has been boiled or treated 
with sterilizing tablets should drink. 
• Eating foods that are freshly prepared and cooked thoroughly. Raw or undercooked 
seafood should not be eaten. 
• Raw vegetables such as green salads, as they may have been washed in contaminated 
water, should be avoided. 
• Good personal hygiene should be maintained. 
4.2 Rehydration therapy 
The key to therapy is provision of adequate rehydration until the disease has run its course 
(usually 1 to 5 days in the absence of antimicrobial therapy). Rehydration can be 
accomplished by intravenous infusion of fluid (in severe cases) or by oral rehydration with 
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an oral rehydration solution (ORS) [67]. For adults, the intravenous replacement solution 
should be infused as rapidly as possible so that about 2 liters is given in the first 30 min. 
Children in shock should receive 30 ml of intravenous fluid per kg of body weight in the 
first hour and an additional 40 ml/kg in the next 2 h. In both adults and children, ORS (with 
its glucose and potassium) should be administered as soon as possible in the course of 
illness. Patients with mild or moderate dehydration can receive initial fluid replacement to 
repair water and electrolyte deficits exclusively by the oral route [68]. 
4.3 Antimicrobial treatment 
Antimicrobial agents can shorten the duration of cholera diarrhea and the period of excretion 
of vibrios. Treatment should be started after vomiting subsides (i .e. , after initial rehydration 
and correction of acidosis). Tetracycline is the drug of choice [67]. Tetracycline may 
provide some protection when given as a prophylactic agent within a family in which cases 
of cholera have occurred [69-70]. However, widespread use of tetracycline prophylaxis has 
been associated with rapid development of antimicrobial resistance [71-72] and should be 
strongly discouraged. Other antibiotics that are effective when V. cholerae are sensitive to 
them include erythromycin, cotrimoxazole, azithromycin, doxycycline, chloramphenicol and 
urazolidone. 
4.4 Vaccine treatment 
One of the main efforts at combating cholera epidemics is directed towards the development 
and use of modem vaccine strategies. Cholera is predicted to have a high potential for 
successful prevention by vaccination [73]. Efficient protection is dependent on the biotype: 
infection with the classical biotype shows more conserved protection against different 
serotypes (lnaba, Ogawa, and Hikojima) of classical strains, and EI Tor-derived protection is 
more labile against different EI Tor isolates. It was also found that naturally acquired 
immunity lasts for at least 3 years, whereas longer immunity depends on the individual [73]. 
Cholera vaccines have been used for llOO years with varying degrees of success [74-75]. 
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5. Natural protection against cholera 
Studies to-date in patients with cholera suggest that different components of the immune 
system, both humoral and cell mediated, innate as well as adaptive, are activated in response 
to natural infection (76-77]. The best studied responses are the humoral immune responses 
and both mucosal and systemic antibody responses have been found to be related to 
protection [7S]. The serological responses such as the complement mediated vibriocidal 
antibody response, antibody responses to lipopolysaccharide (LPS) and CT as well as to 
protein antigens have been found to be significantly increased in response to clinical cholera 
[79]. The antibacterial responses include, in addition to LPS, responses to the toxin-co-
regulated pilus (TCP), which is a colonization factor and potentially protective antigen [SO-
SI], as well as to the mannose sensitive haemagglutinin (MSHA), a type IV pilus antigen 
[S2] which is also immunogenic and gives rise to antibody secreting cell (ASe) responses 
and fecal as well as plasma antibodies in patients [S3]. 
The local secretory IgA response is believed to playa major role in protective immunity 
from diarrhea caused by V. cholerae, since cholera is a human-restricted, noninvasive 
mucosal infection. Cholera also induces both plasma IgG and IgA responses to V. cholerae 
antigens, but only levels of circulating V. cholerae-specific IgA antibodies are associated 
with protection [15]. However, like plasma vibriocidal-antibody titers, plasma IgA responses 
remain elevated for only 6 to 12 months after cholera infection [26], while protective 
immunity after clinical cholera infection lasts substantially longer [33]. 
It has been found that circulating V. cholerae-specific memory B-cells remain detectable for 
at least one year after cholera infection and persist longer than traditional measures of 
immunity to cholera [26] and thus may contribute to long term protection upon re-exposure. 
6. The immune response to pathogens 
The symptoms of an infection result from a complex interaction of microbial factors and 
host responses: in order to produce an infection, a pathogenic microorganism must be able to 
survive in the environment, be transmitted, and establish itself in its host. The immune 
system plays an essential role in host defense [S4]. Following its introduction into a host a 
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pathogen faces what can be artificially divided into two types of immune responses: an 
innate and an adaptive response. These two responses differ in their kinetics, their effectors, 
and the receptors involved. 
6.1 Innate and Adaptive Immunity 
The innate immune system is the first line of the defense system against microbial pathogens 
such as Gram-positive and Gramnegative bacteria, fungi and viruses. Innate immune cells 
such as macrophages and Des (dendritic cells) directly kill the pathogenic microorganism 
through phagocytosis or induce the production of cytokines, which aid elimination of the 
pathogens [85-86]. 
The responses of the innate Immune system instruct the development of long-lasting 
pathogen-specific adaptive immune responses. The adaptive immune system consists of B-
and T -cells, which provide pathogen specific immunity to the host through somatic 
rearrangement of antigen receptor genes. It functions with the following sequence of events: 
antigen presentation, clonal expansion, and differentiation into effector cells, either B or T 
lymphocytes. B-cells produce pathogen-specific antibodies to neutralize toxins produced 
by pathogens, whereas T -cells provide the cytokine milieu to clear pathogen-infected cells 
through their cytotoxic effects or via signals to B-cells [87]. 
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Fig 1.5: The principal mechanisms of innate and adaptive immunity: The mechanisms 
of innate immunity provide the initial defense against infections. Some of the mechanisms 
prevent infections (e.g., epithelial barriers) and others eliminate microbes (e.g., phagocytes, 
natural killer [NK] cells, the complement system). Adaptive immune responses develop later 
and are mediated by Iympbocytes and their products. Antibodies block infections and 
eliminate microbes, and T lymphocytes eradicate intracellular microbes. The kinetics of the 
innate and adaptive immune responses are approximations and may vary in different 
infections. (Basic Immunology: Functions and Disorders o/the Immune System, 3ni Edition, Abul K 
Abbas & Andrew H Lichtman) 
6.2 Primary and secondary immune response 
The immune system mounts larger and more effective responses to repeated exposures to the 
same antigen. The response to the first exposure to antigen, called the primary immune 
response, is mediated by lymphocytes, called naive lymphocytes, which are seeing antigen 
for the fi rst time. The term naive refers to the fact that these cells are " immunologically 
inexperienced," not having previously recognized and responded to antigens. Subsequent 
encounters with the same antigen lead to responses, called secondary immune responses, 
which usually are more rapid, larger, and better able to eliminate the antigen than are the 
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primary responses. Secondary responses are the result of the activation of memory 
lymphocytes, which are long-lived cells that were induced during the primary immune 
response. Immunologic memory optimizes the ability of the immune system to combat 
persistent and recurrent infections, because each encounter with a microbe generates more 
memory cells and activates previously generated memory cells. Memory also is one of the 
reasons why vaccines confer long-lasting protection against infections. Heavy chain istotype 
switching and affinity maturation also increase with repeated exposure to protein antigens. 
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Figure 1.6: Primary and secondary immune responses. Antigens X and Y induce the 
production of different antibodies (a reflection of specific city). The secondary response to antigen X 
is more rapid and larger than the primary response (illustrating memory) and is different from the 
primary response In antigen Y (again reflecting specific city). Antibody levels decline with time after 
each immunization. (Basic Immunology: Functions and Disorders oflhe Immune System, 3'd Edition, 
Abul K Abbas & Andrew H. Lichtman.) 
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6.3 Immunological memory 
Memory lymphocytes can greatly influence immune responses against subsequent 
infections. The ease with which they are triggered [88-89], even at very low antigen 
concentrations, may explain why immune responses tend to be dominated by memory 
lymphocytes from previous infections, a phenomenon termed 'original antigenic sin ' [90-
91). 
During pnmary pathogen encounter, the innate immune system plays a key role in 
determining the nature of the immune response (92). The type of response that is induced is 
detennined by the ' immunological context' of the pathogen, including its localization [93], 
the presence of conserved bacterial peptides [94-95], and the cytokines and chemokines that 
are locally expressed [96-97). Based on these signals, lymphocytes differentiate to a 
memory phenotype and attain a certain effector mechanism. These effector mechanisms are 
recalled whenever effector/memory lymphocytes are re-stimulated by their specific epitope 
(98). When lymphocytes differentiate, their cytokine production is somatically imprinted by 
chromatin remodeling and DNA demethylation. Differentiated lymphocytes thereby 
epigenetically transfer their mode of response to their daughter cells (99). The immune 
system thus learns to associate the antigens it encounters with the appropriate types of 
response against them. 
6.4 B-ceU immunological memory 
Serum and mucosal antibody levels are maintained long term by multiple mechanisms. 
Pathogen re-exposure or booster vaccination is clearly the most effective way to boost 
specific antibody and memory B-cells (MBCs). Long-lived plasma cells are responsible for 
the continuous maintenance of serum antibody levels [100-101)' Memory B cells are 
responsible for driving the rapid anamnestic antibody response that occurs after re-exposure 
to antigen, which is important for eliminating the pathogen and toxic antigens not cleared by 
pre-existing circulating antibodies. Memory B cells may also playa role in replenishing the 
pool of long-lived plasma cells to maintain long-term antibody levels in the absence of 
pathogen (102). A latent or low-grade chronic infection in which sporadic or continuous 
antigenic stimulation occurs also drives B-cell receptor (BCR)-dependent differentiation of 
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B cells into antibody- secreting plasma cells. In the absence of antigenic re-exposure, 
however, long-lived plasma cells (LLPCs) and MBCs can still be maintained for decades 
[103-104). Although antigen is not needed for the survival ofMBCs, the presence of a BCR 
on MBCs as well as on naive B cells is required [105). 
7. Synthesis of immunoglobulins at mucosal surfaces 
In humans, more [gA is produced than all the other immunoglobulin isotypes combined 
[106], and high concentrations of [gA antibodies (over I mg per mJ) are present in the 
secretions that are associated with mucosal surfaces in normal humans [107-108). The 
protease resistance of secretory IgA (sIgA) is a result of its dimerization and high degree of 
glycosylation during its synthesis in mucosal plasma cells, and its association with a 
glycosylated fragment (the secretory component) derived from the epithelial polymeric 
immunoglobulin receptor (PIgR) that mediates transport of dimeric 19A across epithelial 
cells to the lumen (109). 
sIgA has multiple roles in mucosal defense (110). It promotes the entrapment of antigens or 
microorganisms in the mucus, preventing direct contact of pathogens with the mucosal 
surface, a mechanism that is known as ' immune exclusion' . Alternatively, sIgA of the 
appropriate specificity might block or sterically hinder the microbial surface molecules that 
mediate epithelial attachment [III], or it might intercept incoming pathogens within 
epithelial-cell vesicular compartments during pIgR-mediated transport (110). Interstitial 
fluids of mucosal tissues that underlie the epithelial barrier contain dimeric IgA that is 
synthesized by local IgA-secreting plasma cells and this might prevent mucosal-cell 
infection, by mediating the transport of pathogens that have breached the epithelial barrier 
back into the lumen through plgR [112] or by mediating antibody-dependent cell-mediated 
cytotoxicity (ADCC) that leads to the destruction of local infected cells (113). 
Local IgG synthesis also can occur in the mucosal tissues following the administration of 
antigen or vaccine to mucosal surfaces [114). Large numbers oflgG-secreting plasma cells 
are present in the female genital tracts of macaques and humans [114], and high 
concentrations of IgG as well as [gA have been measured in human cervical and vaginal 
secretions [108). This IgG, as well as sIgA, could play a significant role in blocking 
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infection by sexually transmitted pathogens at this site, Concentrations of IgG and IgA in 
secretions of the female reproductive tract are affected by hormonal signals and change 
dramatically during the menstrual cycle, and this might be an important factor in the 
effectiveness of mucosal vaccines against sexually transmitted diseases. In the human 
intestine, 5- 15% of mucosal plasma cells secrete IgG [115], but IgG is susceptible to 
degradation by luminal intestinal and bacterial proteases. In large intestinal secretions, for 
example, IgG concentrations are generally 3 to IOO-fold lower than those of sIgA [116]. 
Nevertheless, intact IgG in mucosal tissues, whether locally produced or from serum, can 
potentially neutralize pathogens that enter the mucosa and prevent systemic spread. In recent 
study on mucosal immunologic responses, significant level of V. cholerae 
lipopolysaccharide (LPS)-specific sIgA and IgG were found for a period of one month after 
natural infection [I 17]. 
7.1 Mucosal immunity and vaccine development 
An effectively designed mucosal vaccine must: (I) protect from physical elimination and 
enzymatic digestion, (2) target mucosal inductive tissues including M cells, and (3) 
appropriately stimulate the innate immune system to generate effective adaptive immunity. 
In mucosal vaccine development, it is crucial to select appropriate immunization route, and 
most current mucosal vaccine delivery is intended to mimic the nature encounter of mucosal 
inductive sites with environmental antigens and pathogens. 
Mucosal immune responses are most efficiently induced by the administration of vaccines 
onto mucosal surfaces, whereas injected vaccines are generally poor inducers of mucosal 
immunity and are therefore less effective against infection at mucosal surfaces [118]. By 
contrast, our understanding of mucosal immunity and development of mucosal vaccines has 
lagged behind, in part because administration of mucosal vaccines and measurement of 
mucosal immune responses are more complicated. The dose of mucosal vaccine that actually 
enters the body cannot be accurately measured because antibodies in mucosal secretions are 
difficult to capture and quantitate, and recovery and functional testing of mucosal T cells is 
labour intensive and technically challenging. As a result, only a few mucosal vaccines have 
been approved for human use in the United States or elsewhere. These include oral vaccines 
against poliovirus, Salmonella Typhi, V. cholerae and rotavirus, and a nasal vaccine against 
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influenza ViruS [119]. However, research and testing of mucosal vaccmes is currently 
accelerating, stimulated by new information on the mucosal immune system and by the 
threat of the mucosally transmitted virus, HIV [120-121]. 
8. Vaccines against tbe patbogenic diseases 
Vaccines represent the epitome of a preventive strategy to control disease [122]. In the 
individual, they confer direct protection and, if high enough immunization coverage of a 
population is achieved, unimmunized people may also be protected, indirectly, through 
'herd immunity' [123]. The strategic use of some vaccines, such as measles and polio 
vaccines, has interrupted indigenous transmission of those diseases in entire regions of the 
globe [124-125]. And one disease, smallpox, has been completely eradicated from the 
human population through the epidemiologically sound use of smallpox vaccine [126-127]. 
In developing countries, where two-thirds of the world's populations live, infectious 
diseases cause most of the mortality among children less than 5 years of age [128] and 
constitute major health problems in older children and adults. Vaccines are among the most 
promising interventions to diminish the burden of specific infections in populations in 
developing countries [129-130]. 
8.1 Cholera prevention by vaccination 
Beside hygienic and sanitary control measures and cholera surveillance, one of the main 
efforts at combating cholera epidemics is directed towards the development and use of 
modern vaccine strategies. Cholera is predicted to have a high potential for successful 
prevention by vaccination [73]. Injectable, killed whole-cell (We) cholera vaccines date 
back virtually to the discovery of the cholera vibrio in the nineteenth century. These 
vaccines fell from favor in the 1970s because they were found to confer low levels of 
efficacy of short duration and to have an unfavorable safety profile [131]. Currently, these 
vaccines are not recommended for use. Attention shifted from parenteral to oral vaccines 
against cholera with the recognition that protective immunity against cholera results 
primarily from local, mucosally secreted intestinal antibodies and that oral presentation of 
antigens is an efficient method of eliciting intestinal mucosal immune responses. In 
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comparison with parentally delivered vaccines, oral vaccines are easier to administer, more 
acceptable to recipients, and have a reduced risk of transmitting blood-borne infections 
[ 132]. 
Cholera vaccines fall into two broad categories: heat or formalin-inactivated whole cells 
(WC) and genetically attenuated live vaccines. Both vaccine types have advantages and 
drawbacks. For instance, field trials of the WC/CTB in Bangladesh and Peru have shown 
that the vaccine is safe and induced 85- 90% protection after a two-dose administration 
regime [133]. However, protection declined rapidly after six months, particularly in 
children. A variant of the WC/rCTB lacking rCTB has been tested in Vietnam and shown to 
have 66% efficacy after eight months among all age groups [134]. Live genetically-
attenuated vaccine candidates date back to the pioneering work of Finkelstein et aI. who 
developed the N-methyl- N'-nitro-N-nitrosoguanidine-induced non-toxigenic and 
immunogenic EI Tor biotype vaccine candidate Texas Star-SR [135]. 
8.2 WHO recommendations on vaccines 
In a recent position paper of WHO [136] the following recommendation is given: "Among 
the new generation cholera vaccines, convincing protection in field situations has been 
demonstrated only with the WC/rBS vaccine. Thus, WC/rBS (Dukoral) vaccine should be 
considered in populations believed to be at imminent risk of a cholera epidemic". £t is also 
recommended to travelers. Although live attenuated genetically modified strain CYD I 03-
HgR is not recommended by WHO, for immunization of travelers to highly endemic areas 
its use is considered acceptable by WHO 
9. Killed we Vaccine with Cholera Toxin B Subunit: Dukoral 
Dukoral is a WHO recommended cholera vaccine. This oral cholera vaccine developed by 
Swedish scientists was licensed in Bangladesh in 2007 by Healthcare Pharmaceuticals 
Limited (HPL). Dukoral has been licensed for persons two years and above. The 
manufacturer recommends that the vaccine be given in two doses 7-14 days apart for adults 
and children six years and older, and in three doses for children 2-5 years 01d20. Boosters 
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are recommended every two years for persons six and above, and every six months for 2-5 
year olds. 
9.1 Composition of Dukoral 
Dukoral consists of a mixture of four preparations of heat- or formalin-killed whole-cell V 
cholerae 01 , representing both serotypes Inaba and Ogawa and both biotypes classical and 
EI Tor (Table-I.I), that are then added with purified recombinant cholera toxin B subunit 
(rCTB) (produced in V cholerae 01 Inaba, classical biotype strain 213). Because CT cross-
reacts with E coli LT, the vaccine also provides short-term protection against ETEC, which 
is of added benefit [137-138]. 
Dukoral contains 1 mg recombinant non-toxic B-subunit of the cholera toxin (rCTB) and 1 x 
II 10 
10 vibrios of killed whole V cholerae 01 bacteria, i.e. 2.5 x 10 vibrios each of: 
Table-I.]: Qualitative and quantitative composition ofDukoral vaccine 
Serogroup Serotype Biotype nactivation process N umber of bacteria 
Vibrio cholerae 01 Inaba Classical Heat inactivated 25xlO' bacteria 
Vibrio cholerae 01 Inaba EI Tor Formalin inactivated 25x 1 0' bacteria 
Vibrio cholerae 01 Ogawa Classical Heat inactivated 25x 1 0' bacteria 
Vibrio cholerae 01 Ogawa Classical Formalin inactivated 25x I 0' bacteria 
(*Bactenal count before maCtIvatlOn.) Each dose ofvaccme contams 3 ml suspensIon. 
The vaccine is a whitish suspension in a single-dose glass vial. The sodium hydrogen 
carbonate is supplied as white effervescent granules with a raspberry flavor, which should 
be dissolved in a glass of water. Each dose of vaccine is supplied with one sachet of sodium 
hydrogen carbonate. The vaccine is taken orally with bicarbonate buffer, which protects the 
antigens from gastric acid. 
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Figure 1.7: Dukoral vaccine. (http://www.mynewsdesk.comlfiles) 
9.2 Efficacy of Dukoral 
The vaccine has been evaluated in a number of well-designed field trials; the original and 
largest field trial was carried out in Bangladesh [139-140]. In this trial, individuals received 
a total of 3 doses of the vaccine at 6-week intervals. WC-BS induced a high level of 
protection (85%) during the initial 6 months of the study [139]. At 12 months offollow-up, 
the vaccine was 62% protective. At 36 months of follow-up (the end of the study), WC-BS 
was 50% protective. During the first 6 months of evaluation, the vaccine provided protection 
in both young and older children, as well as in adults. However, the protective effect in 
young children rapidly decreased, and at 36 months of surveillance, the vaccine had its 
lowest efficacy (26%) among children aged 2- 5 years, compared with 63% among 
individuals aged 15 years [140]. The vaccine protected equally against mild and severe 
cholera. 
Immunologic responses after exposure to V. cholerae 01 vary by biotype and serotype, and 
although protection against disease caused by classical or EI Tor biotypes was equivalent 
during the first 6 months of surveillance after vaccination, the longer term efficacy of WC-
BS at 3 years was found to be lower against infections due to the EI Tor biotype (39"10) than 
against those due to the classical biotype (58%) [140]; the current global pandemic is caused 
predominantly by V. cholerae 01 EI Tor organisms. The protective effect was also lower in 
individuals with blood group 0 (a risk factor for cholera gravis). The vaccine induced short-
lived protection (67% at 3 months of surveillance and 21% at 12 months of surveillance) 
against heatlabile enterotoxin- producing enterotoxigenic Escherichia coli (ETEC) [137, 
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141]. Over the 3-year follow-up period, WC-BS resulted in a 2S% reduction in hospital 
admissions of individuals with all types of diarrhea in Bangladesh, a SO% reduction in 
hospital admissions for life-threatening diarrhea, and a 4S% reduction in mortality in women 
aged lIS years during a cholera epidemic [142]. 
Later, the production technology ofWC-BS vaccine was modified: B subunit was prepared 
by recombinant genetic technology (WC-rBS). This vaccine was tested in multiple clinical 
trials in Peru in the 1990s. A trial in a cohort of adult military volunteers confirmed that the 
vaccine confers highgrade protection (86%) against EI Tor cholera in the short term [143]. 
Another trial, performed in the general population, failed to find protection during the year 
after a 2-dose regimen but observed that a single booster dose given a year after the primary 
regimen elicited robust protection [144]. Because of methodological problems with the latter 
trial, a 2-dose regimen of WCrBS has been licensed internationally on the basis of the other 
cited trials [14S]. A 2-dose regimen of WC-rBS was administered in a mass vaccination 
program in 2003 and 20004 in Beira, Mozambique, and was found to confer 84% protection 
to all persons aged ~2 years and 82% protection to children vaccinated at <S years of age 
[146]. 
9.3 Limitations of Dukoral 
Unfortunately the dukoral vaccine also has some drawbacks which limit its practical 
application [147]. 
~ The price is still too high to be useful in poor countries in a sustained manner. 
~ It must be kept in the refrigerator and the packaging is quite bulky limiting its 
distribution in the country. 
~ Finally, though rather simple for health providers to administer to patients, training 
and paying these health providers is a major constraint for the health system. 
Due to these drawbacks the vaccine's capacity to reduce the cholera burden in Bangladesh 
and other cholera endemic countries has become limited. Nevertheless the launch ofDukoral 
in Bangladesh is a welcome step toward the eventual control of endemic cholera 
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10. Modified killed WC-only vaccines: ShanChol 
The earlier version of the Vietnamese vaccine (ORC-Vax) was found to contain residual 
cholera toxin. To address these issues, a new bivalent (01/0139) vaccine has been created 
in which a high toxin-producing strain (classical lnaba 569B) has been replaced by 2 
alternative strains: heat-killed classical Inaba Cairo 48 and formalin-killed classical Ogawa 
Cairo 50. LPS content has been doubled, and modem quality control and release assays are 
used, including one to verilY the absence of cholera toxin in the final product [148]. 
Several trials have evaluated a 2-dose regimen of this modified WC vaccine. The vaccine 
was shown to be safe and highly immunogenic against V. cholerae 01 , with seroconversion 
rates of vibriocidal antibodies of 91 %among adults in Vietnam [149], 53% among adults in 
Kolkata, and 80% among children aged ~1 year of age in Kolkata, where high background 
immunity exists (19]. A phase ill trial of the vaccine among :::70,000 adults and children ~ l 
year of age in slum areas of Kolkata, India, found that, during 2 years of follow-up, the 
vaccine conferred 67% protection against treated episodes ofEI Tor cholera [23]. Protection 
was sustained at this level during the third year, and surveillance continues. Interestingly, all 
cholera isolates detected in this trial exhibited the features of newly emergent modified EI 
Tor cholera described earlier. Protection against 0139 cholera was not evaluable. 
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Figure 1.8: ScahnChol Vaccine. 
(http://choleral .wikispaces.comlfileiview/Shancholyic380jpgl205284838/Shancholyic38 
Ojpg) 
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In collaboration with the Government of Bangladesh, icddr,b is launching a five year long 
project to assess the feasibility of using an oral cholera vaccine, ShanChol produced in India 
which has whole cell components but not CTB. Evidence-based data show that increasing 
rates of cholera and diarrheal patients are coming to the icddr, b diarrhea hospital from the 
northern part of Dhaka city, and therefore this area has been chosen to receive the vaccine. 
ShanChol is being used in a large feasibility study in Bangladesh. About 160,000 people 
above the age of one year will be vaccinated, excluding pregnant women. The project has 
two components: vaccine provision and behavior change communication for promotion of 
hand washing and safe water treatment. The icddr,b is evaluating the effectiveness of 
vaccinating a large number of people from this area against cholera. Killed cholera vaccines 
have already been successfully introduced in countries like Vietnam (around 1997) and 
India (in 2009). The chosen vaccine Shanchol is safe, affordable and effective in preventing 
cholera. 
11. Cholera vaccine CVD l03HgR 
The Center for Vaccine Development (CYO) at the University of Maryland developed a live 
attenuated cholera vaccine derived from the classical Inaba 569B strain in the I 980s. It was 
engineered to express the cholera toxin B subunit, with most of the active A subunit deleted 
to remove its tox.icity. The vaccine has the advantage of being administered in a single dose. 
Protective efficacy was studied in seven ex.perimental challenge studies in North America 
involving a total of 103 vaccinees and 86 unvaccinated controls. In these studies, vaccinees 
were challenged with virulent EI Tor Inaba (N=34), El Tor Ogawa (N=30) or classical Inaba 
(N=39) strains at different points in time (varying from 8 days to six months after ingestion 
of a single oral dose of CYO 103-HgR. Vaccine efficacy in preventing moderate or severe 
cholera ( ~3 . 0 liter purge) was found to be 100% against classical and 95% against El Tor 
cholera, and 76% in preventing diarrhea of any [ISO]. These studies showed the vaccine to 
protect North American volunteers against both classical and El Tor strains, beginning as 
early as eight days following vaccination and persisting for at least six months [151]' The 
vaccine was shown to be safe and immunogenic in a series of Phase I and II randomized, 
controlled clinical trials in adults and children in Asia, South America and Africa [152]. 
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Based on the results in U. S. volunteers, the CVD 103-HgR vaccine achieved licensure in 
1993 as a traveler' s vaccine in several countries. It was produced by Bema Biotech (now 
Crucell) and sold as Orochol (or Mutachol) in single-dose, double-chambered sachets that 
contain the freeze-dried vaccine in one chamber and a sodium bicarbonate butTer in the 
other, which is required to protect the B subunit and live vibrios against gastric acid. The 
vaccine is reconstituted by mixing it and the buffer in 100 ml of water. Two different dosage 
amounts were available - one for developed countries and another, with ten times as many 
organisms, for developing countries [151]. 
12. Other cholera vaccines in pipe line 
Several experimental live oral candidate vaccines are under development. A live vaccine, 
Peru 15 is a genetically attenuated V cholerae 01 EI Tor Inaba strain, originally isolated in 
Peru in 1991 . A single-dose regimen of Peru 15 has been shown to be safe and immunogenic 
in the US volunteers, as well as in adults and toddlers in Bangladesh [35]. 
V. cholerae 638 is an attenuated 01 EI Tor Ogawa strain that is being developed in Cuba. A 
single-dose regimen was shown to be immunogenic and protective in an experimental 
cholera challenge study in Cuban adults [153]. V. cholerae IEM 101 is an 01 EI Tor Ogawa 
strain from China that naturally lacks the gene for cholera toxin and several other virulence 
factors . In human studies, it was found to be immunogenic with no adverse effects. Two 
additional derivatives- IEM 108 and 109- are also promising candidates, but no human 
data have been reported to date [154-155]. 
Another interesting V. cholerae 01 candidate IS the VA!.3 from India, which IS a 
recombinant strain able to produce CTB but which is otherwise devoid of cholera toxin. This 
vaccine was found to be safe and immunogenic in adults in Kolkata [156]. Two recombinant 
live attenuated Vibrio 0139 candidate vaccines, CVD 112 and Bengal 15, have been 
evaluated in volunteer trials, and they provided :::80"10 protection against challenge with 
wild-type 0139 strains [157-158]. 
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13. Objectives of the study 
The main objective of the study was to evaluate memory B-cell immune responses to two 
major antigens, CT and LPS of V. cholerae 0 I, in children and adults after oral cholera 
vaccination. 
Specific aims of the study were to: 
• ascertain how well memory B-cells are generated after vaccination with Dukoral 
• determine the longevity of memory 8-cell responses after vaccination 
• compare antigen specific memory 8-cell responses among children and adults. 
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CHAPTER TWO 
MATERIALS AND 
METHODS 
1. Study site 
This study was carried out in the Laboratory Sciences Divisions (LSD), International Centre 
for Diarrheal Disease and Research, Bangladesh (icddr, b) . All the vaccinations were carried 
out in healthy people living in the Mirpur area in Dhaka, Bangladesh. The study was 
approved by the Research Review Committee (RRC) and Ethical Review Committee (ERC) 
of the icddr, b. 
2. Study participants 
The study populations were aged ranges from 2 to 17 for children and from 18 to 45 for 
adults. From all the study participants blood samples were obtained before vaccination (day 
O) and after vaccination at day 3, 21 , 30, 90 and 180 from child vaccinees and for adults 
after 3, 17, 30, 90 and 180 day of each dose. Participants were excluded from the study if 
they had a history of gastrointestinal disorder or diarrheal illness in the past 2 weeks, febrile 
illness in the preceding week or received antibiotic treatment at least 7 days prior to 
enrollment; or that were positive for common enteric pathogens were also excluded. The 
vibriocidal assay, enzyme linked immunosorbent (ELISA) assay for serum IgG and 19A 
antibodies to CTB and LPS (V. cholerae-specific Ogawa), and for antigen-specific JgG, JgA 
memory B-cells enzyme linked immunospot (ELiSPOT) assays were performed for each 
time period. 
3. Study design 
3.1 Vaccination 
The oral monovalent WC-O I/CTB , cholera vaccine (Dukoral) was studied (SBL Vaccine, 
Stockholm, Sweden). The vaccine contains 1.0 x 10" heat- and formalin-killed 01 Vibrios 
(both Inaba and Ogawa serotypes, and classical and EI Tor biotypes) together with 1.0 mg of 
recombinantly produced cholera toxin B (rCTB) subunit. 
After venous blood was collected from participants, they were given a single dose of 
Dukoral. This is provided as an oral liquid suspension in a single dose glass vial with 
bicarbonate, citrate and ascorbic acid buffer. Vaccine was added to 150 mI of buffer, wbich 
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protects the antigens from degradation by gastric acid. The formulated vaccine was given 
within an hour of preparation. On the other hand the second dose was give after 14 days of 
first dose. Food and drink were withheld for I h before and 1 hr after vaccination. 
3.2 Blood sample collection 
In case of adult and child vaccinees, two doses of vaccine were given at two times interval-
one at day 0 and the next one was at day 14. For adult vaccinees, 8 to 12 ml of blood was 
collected in a sodium heparinized vacutainer tube from each vaccine participant at 6 times 
point during the duration of the study. Blood samples were collected from vaccine 
participants at day DO (before vaccination), and at D3, D 17, D30, D90 and D 180 after 
vaccination (Fig 2.1). 
1 sl dose vaccination 
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DO D3 
t i 
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DO (before 
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017 (03 after 2nd 
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i i 
DJO D90 D180 
T i i 
Blood collection at D30, 090, 0180 
(after 1" dose of vaccination) 
Figure-2.l: Blood collection schedule for adult vaccinees: Oukoral cholera vaccine was 
given at day 0 and day 14 and blood samples were collected from vaccine participants at day 
0(00) before vaccination, and at day 3, 17, day 30, day 90, dayl80 after vaccination 
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For child vaccinees, 8 to 10 ml of blood was collected in a sodium heparinized vacutainer 
tube from each vaccine participant at 6 times point during the duration of the study. 
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Figure-2.2: Blood collection schedule for child vaccinees: Dukoral cholera vaccine was 
given at day 0 and day 14 and blood samples were collected from vaccine participants at day 
o (DO) before vaccination, and at day 3, day 21, day 30, day 90, day 180 after vaccination 
4. Laboratory metbods 
4.1 Bacteriological examination of patient stools 
Stool from patients with a characteristic rice watery appearance were screened by dark-field 
microscopy for the observation of the darting movement by its flagella to confirm Vibrios 
infection. Inhibition of its movement by antibodies specific for V. cholerae 0 I or V. cholerae 
0139 confirmed the serotype. Inaba or Ogawa specific antibodies inhibition screening 
confirmed the biotype of the V. cholerae 0 I. 
4.1.1 Dark field microscopy to diagnose cholera in diarrheal stools 
Dark field microscopy (DF) is a microscope based technique to detect motile V. cholerae in 
stool sample .The genus Vibrio is named for the unique, rapid to- and fro- motility, which is 
characteristic of this group of organism. By using this property, the organisms were detected 
in DF. In the microscopic field, the specimen illuminates and the field around the specimen 
remains dark. Live and motile V. cholerae can be seen directly without the help of staining 
by this quick technique (Fig 2.3). For this technique, a small drop of the test stool sample 
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was placed on a clean slide by a bacteriological loop and a clean cover slip was applied on to 
it Emulsion oil was applied on the lens to help the visibility of the object The slide was 
examined under dark field at 40X magnifications. Organisms with typical motility were 
observed and sample was defined as DF+ for infected patients. This confirmed V. cholerae in 
the patients sample. Inhibition of motility by strain specific antibodies was used to confirm 
the serogroup of the pathogen. 
~ , 
• 
•• 
, 
. \
• , , , 
\ 
., 
, , 
, 
.- • ',' 
";I 
• 
,. , 
.. 
.. - f 
.... I 
I 
Figure-2.3: Dark field microscopy of Vibrio cholerae. (http://cdn.physorg.com) 
4.2 Serological detection of Vibrio cholerae 01 
Stool sample from the diarrheal patients were plated on TIGA plate. Grayish colonies with 
a central dark zone surrounded by a zone of opacity were observed typical for V. cholerae 
(Fig-H). 
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Figure-2.4: Vibrio cholerae colonies on ITGA plate 
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For serotyping, V. cholerae 01- or V. cholerae 0139-specific mouse monoclonal antibody 
sera were used. Mouse anti-serum was raised against V. cholerae 01 for both Inaba and 
Ogawa serotypes. For serotyping, a slide was taken and divided into three parts (Fig-2.S). 
Then three types of antisera (V. cholerae 01- Ogawa, V. cholerae 01- Inaba and V. cholerae 
0139-specific rabbit antisera) was dropped on each part of the slide. Bacteria from the 
TTGA plate were applied on the slide where antibody was present. Agglutination was 
observed when specific colony for the antisera was present. The occurrence of clear 
agglutination within 2 minutes was considered a positive reaction. Only V. cholerae 0 I 
reacting samples either Ogawa or lnaba were enrolled in this study. 
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Figure-2.5: Serological detection of V. cholerae 01: Coagulation is seen at the first 
portion of the slide indicates antisera containing anti Ogawa antibody cross links V. cholerae 
and gives a spotted colour. 
4.3 Isolation of peripberal blood mononuclear cells (PBMC) 
a) Heparinized venous blood was diluted with equal volume of Phosphate Buffered 
Saline (PBS, 10 mM, pH = 7.2) in Falcon tubes. 
b) Diluted blood was carefully added to the volume of Ficoll-Isopaque (in a I: 1 ratio of 
undiluted blood) without disturbing the Ficoll layer. Hence, two distinct layers were 
maintained. 
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c) The tube was centrifuged at 772 g for 25 minute at 20°C. 
d) After centrifugation, PBMCs were remained at the interface of plasma and Ficoll . 
RBCs and other cell debris were precipitated at the bottom of the tube. The 
mononuclear cells were then removed from the top of the Ficolliayer carefully with a 
Pasteur pipette. 
e) The PBMCs were washed once in PBS at 952 g for 10 minute at 20°C. 
f) The PBMCs were resuspended in 10 ml of PBS. 25~ of cell suspension was collected 
into an eppendorf tube (25~ cell suspension with 25~ tryptan blue) and then MNCs 
were counted in the haemocytometer while the resuspended PBMCs were washed for 
the second time at 953 g for 10 minute at 20°C. 
g) After the second wash, the cells were resuspended in RPMl Complete medium to a 
concentration of I 07cell s/m I. These cells were used for antigen-specific ASC-ELISPOT 
and for memory B cell culture. 
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Figure-2.6: Isolation of PUMC by density gradient centrifugation on Ficoll-Isopaque. 
(http://www.currentprotocols.com/protocoVmca04c) 
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Flow Cbart Describing tbe Study 
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4.4 Enzyme linked immunospot (ELISPOT) assay 
The B-cell ELISPOT is a highly sensitive assay that allows the detection and enumeration of 
antibody secreting cells; although the number of spots are not a direct reflection of this as 
proliferation of cells occurs during the 6-day culture. The assay can be used for the detection 
of antigen-specific responses as well as for determinations of the total number ofIg-secreting 
cells. By use of isotype specific reagents, cells producing antibodies of different isotypes 
(IgG, IgA) can be analyzed separately. This assay is highly sensitive, quantitative, easy to 
use and amenable to high throughput. 
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Figure-2.7: General outline of ELlS POT assay. 
1) Antigen is immobilized on the membrane of a 96-well ELI SPOT plate. 
2-4) Cells are added and left to incubate to allow secretion and binding of antigen-specific 
antibodies. 
5) After removal of the cells. bound antibodies are detected with HRP-co}ugated anti-lg. 
6-7) Spots are visllalized by the addition of AEC (amino ethyl carbazole)-H:/h SlIbstrate. 
8) Evaluation and counting of spots are made in a microscope 
In single color ELISPOT assay separate wells are used for development of IgA and IgG 
secreting cells. Red spots indicate 19A specific ASe, blue spots indicate only IgG specific 
ASe. (http://www.biotek.comlresourceslarticleslautomating-wash-elispot.html) 
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4.4.1 Coating the plates for Memory B-cell study 
a) Nitrocellulose plates were coated with 100111 of: 
• GM1 , at 3nmoVml in PBS for Cholera Toxin 
• Goat anti-human IgG at 3.0 Ilg 1m! in PBS for the total - Immunoglobulin plate and 
• KLH, at 2.5ug/m! in PBS for negative control. 
LPS (Ogawa) Plate coating: 
• 50 III ofpoly-L-Lysine solution (conc. 101lg/m! PBS) was added to each well. It was 
then kept at room temperature for at least 30 min. 
• The solution was decanted and immediately 50 III bacterial suspension (whole cell at 
conc. of5 .5xI09) or LPS (25 Ilg/ml in PBS) was added to each well. 
• The plates were centrifuged at 2000 rpm for 5 min. 
• ft is recommended not to decant the content (nothing is left actually). 50 III of 0.5% 
gluteraldehyde was added gently. This step should be carried out inside hood, 
because gluteraldehyde is toxic (put on gloves). 
• Plates were kept at room temp for 15 min. 
• Plates were washed twice with PBS (gently). 
• 200 III 0.1 % BSA in 0.1 M glycine was added to each well. 
• Plates were kept at room temp for 30 min. 
• Plates were washed twice with PBS. 
• These plates are ready to use. 
• To store, 200 III 0.1 % BSA-PBS was added to each well and kept at - 20°c. 
b) Plates were incubated at 40 C overnight. 
c) The GMI coating buffer was decanted and the CT plate was washed 3 times with PBS. 
Excessive liquid was removed. 100111 of recombinant cholera toxin B-subunit (rCTB) 
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(2 . 5~g/ ml in PBS) was added to each of the GMI coated wells and PBS to the other 
wells (I OO~l/well ) . The plates were incubated for one hour at 37°C. 
4.4.2 Blocking 
a) Plates were washed twice gently with PBS only. 
b) Next the plates were blocked for 30 minutes-I hour with 200 ~I RPMI complete media at 
37°C. 
4.4.3 Memory B-cell culture and ELISPOT assay for antibody secreting memory 
B-cells 
Memory B cell (MBC) assays were performed as described below. Briefly, PBMC were 
placed in MBCS culture medium optimized to stimulate antigen-independent proliferation 
and terminal differentiation of memory B cells into ASC or medium alone as a negative 
control. This stimulation medium included CpG oligonucleotide, a dilution of crude 
pokeweed mitogen (PWM) extract, and a dilution of fixed Staphylococcus aureus Cowan 
(SAC). Cultures were incubated for 5-6 days, after which antigen-specific and total IgG, and 
total IgA ELISPOT assays were performed. Plates coated with keyhole limpet hemocyanin 
(KLH) were used as negative controls. Appropriate stimulation was defined as the 
stimulation medium generating greater than 4-fold increase of total IgG and IgA ASC as 
compared to the unstimulated cells. 
4.4.3.1 Mitogens for the stimulation cocktail 
I. Pokeweed Mitogen (PWM); diluted to a working concentration of I : I 00,000 in 
Culture Stimulation media. 
II . Staphylococcus aureas Cowan (SAC) fixed; diluted to a working concentration of I : 
10,000 in Culture Stimulation media. 
ill. CpG [T*C*G*T*C*G*T*T*T*T*G*T*C*G*T*T*T*T*G*T*C*G*T*T (* signifies 
phosphothionation) from operon]; diluted to a working concentration of 6~g/ml in 
Culture Stimulation media. 
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4.4.3.2 Memory B-cell culture 
a) Culture wells were divided into unstimulated and stimulated wells. One ml of stimulation 
media was added to respective culture wells using sterile technique. Sterility was very 
critical in this particular step. 
b) To each of these wells 5 x 105PBMC were added in a biohazard hood. 
c) These culture plates were incubated in 5% CO2 at 31'C for 5-6 days. 
4.4.3.3 Antigen specific memory B-Cell ELISPOT assay 
Culture cell harvest: 
~ After 5-6 days proliferation culture cells were collected in eppendrof tubes from each 
culture well . 
~ Centrifuge at 2500 rpm for 7 minutes 
~ Again centrifuged at 2500 rpm for 7 min with PBS only 
~ Finally, cell pellet was resuspended in 200 !!L RPMI complete media which contains 
approximately 5 x 105 Peripheral Blood Mononuclear Cells. 
Cell loading and plate developing: 
~ The blocking solution was decanted. From each culture well , 20% of cells were used 
for total [g' s ELlSPOT, while 80% were used for antigen specific ASC ELlSPOT. 
Keeping this in mind, in the CT and LPS-plates, 40 !!L of fresh RPMl complete 
media was added to the first row and 160 III to subsequent rows. For the Total Ig'·s 
plate, 160 III of fresh media was added to the first row and 180 III to subsequent rows. 
~ 160 III of the resuspended cells were added to each well for the neat well for CT, and 
LPS specific wells and remaining 40 III of resuspended cells were added to the first 
row of total Ig' s plate. 
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~ Four lOx dilutions of the totallg' s wells (transferring 20 ~l), and two 5x dilutions of 
the CTB, and LPS wells (transferring 40 ~l) were carried out. The plates were 
incubated with cells for 5-6 bours at 37°C in a CO2 (5%) incubator. 
~ Next the cells were decanted and the plates washed 5 times with PBS-Tween (0.05%) 
and 3 times with PBS. Excess liquid was shaken off in such a manner so that the 
nitrocellulose membrane does not become dry. 
~ Anti-human IgA-HRP at I :500 and anti-buman IgG-HRP at 1:500 was diluted in 1% 
FBS in PBS-Tween 0.05%. To each well 100~1 was added. All plates were incubated 
overnight at 4°C. The liquid was decanted and plates washed 5 times with PBS-
Tween and 3 times with PBS. 
~ HRP chromogen/substrate, AEC!H20 2• was prepared in advance up to two weeks and 
stored at 4°C. (AEC/ H20 2 preparation: 10 mg of AEC in 1 ml of DMF + 29 ml of 
Na-acetate then filtered through 0.2 ~m). 5~1 of 30% H20 2 was added to 10 ml of 
AEC solution and was vortexed well. 100~1 oftbe chromogen/substrate was added to 
every well and the color reaction monitored immediately. 
~ When the spots were clearly visible, the reaction was stopped by washing the plates 
repeatedly with tap water. 
~ Plates were then soaked in tap water for 30 min before allowing them to dry in room 
temperature. 
~ The spots were counted under low-magnification and the plates stored away from 
light for automated counts later. 
~ Each red spot represented an IgA secreting cell in anti-human IgA-HRP conjugate 
added wells while every red spot indicated an IgG secreting cell in anti-human IgG-
HRP conjugate added wells. 
~ Data was evaluated as CTB and LPS specific IgG/A ASC divided by total IgG/A 
ASC and per 106 PBMC. And the results were expressed as percentage. 
~ We defined appropriate stimulation ofPBMC in our assay as a ~ 4 fold increase in 
the number of total Ig memory cells following stimulation as compared to the 
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unstimulated cells. This definition included approximately 90% of all stimulated 
cultures for both IgG and IgA memory cells . 
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Figure-2.8: An ELISPOT plate well sbowing red spot as IgA. (http://www.piercenet.com) 
4.4.3.4 Antibody in memory B cell culture supernatant (ALS) collection 
Supernatants were collected on the day of harvest, after 5-6 days of incubation using the 
mitogen cocktail described above, and mixed with a protease inhibitor (10 I!Vml) cocktail 
consisting of aprotinin (Il!glmI), leupeptin (101!M), sodium azide (lmglml) and 4-(amino 
ethyl) benzene sulfonyl fluoride (0.21!M) and were then aliquoted and frozen at -70°C until 
assayed for antigen specific IgG and IgA by ELISA. 
4.5 Enzyme linked immunosorbant assay (ELISA) 
ELISA is a qualitative and quantitative immunoassay in which antibodies or antigens are 
detected by the binding of an enzyme coupled to either anti-Ig antibody or antibody specific for 
the antigen. 
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Figure-2.9: Indirect ELISA to detect presence of antibody. 
(http://www.dr.marahimi.com/wpcontentiuploadS/2011 /09/6.jpg) 
.. 
4.5.1 Detection of IgA and IgG antibodies against B subunit of cholera toxin 
(CT) in plasma samples using GMl-ELISA 
Coating 
Wells of polystyrene plates were coated with 100!!LIwell of GMI at a concentration of 
0.3nmol/mL or 0.51lg/ml in PBS. The plates were then incubated at room temperature for 
overnight. Following overnight incubation, the ELISA plates could be stored at 4°C up to 2 
weeks for further use. 
Blocking 
The GMI-coated plates were washed thrice with PBS and blocked with 0.1% Bovine Serum 
Albumin in PBS (BSA-PBS), 200!!L/well for 30 minutes at 37°C. 
Loading of Samples and Plate developing 
}> The plates were washed thrice with PBS-0.05% Tween and once with PBS. 
}> The purified rCTB (0.51lg/m1 in PBS) diluted in 0.1% BSA-PBS were added, 100!!L 
per well and incubated for 60 min at 3 rc. 
}> The plates were washed 3 times with PBS - Tween (0.05 %) and once with PBS. 
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~ The plates were washed 3 times with PBS- Tween (0.05 %) and once with PBS. 
~ The horseradish peroxidase (HRP) conjugated rabbit anti-human IgA and anti-human 
IgG (Jackson ImmuriResearch Laboratories Inc.) were diluted in 0.1% BSA-PBS Tween 
and added 100 111 per well . 
I. Anti-human IgA HRP (e.g. Jackson 309035011 , 111000) 
II. Anti-human IgG HRP (e.g. Jackson 309035006, 111000) 
~ The plates were incubated for 90 min at 3i>C. 
~ The plates were washed 3 times with PBS- Tween (0.05 %) and once with PBS. 
~ The plates were developed with the substrate orthophenylene diamine (OPD)-I 00 111 
/ well, prepared by dissolving 10 mg of OPD in 10 ml of 0.1 M sodium citrate 
buffer, (PH 4.5) to which was added 4 111 of 0.1 % H20 2 immediately before use. 
~ The plates were read kinetically at 450 nm for five minutes. The maximal rate of change 
in optical density in milli absorbance units per minute was normalized across plates by 
calculating the ratio ofthe test sample to a standard of pooled convalescent-phase serum 
from previously-infected cholera patients, which was added as a positive control on each 
plate. For the crn antigen, individuals with a 2:2-fold increase in antibody titer one 
or three weeks post infection or vaccination were considered as responders. 
4.5.2 Detection of 19A and JgG antibodies against Lipopolysaccharide in plasma 
samples using ELISA 
Coating: 
The ELISA plates were coated with \OO~weli ofLPS of V. cholerae 01 at a concentration of 
2.511g1ml in PBS (pH 7.2-7.4). The plates were then incubated at room temperature for 
overnight. Following overnight incubation, the ELISA plates could be stored at 4°C for a week. 
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Loading of Samples and Plate developing 
» The plates were washed 3 times with PBS-Tween (0.05 %) and once with PBS. 
» The plasma samples (initial dilution I :25 for IgA & IgG) diluted in 0.1 % BSA-PBS 
containing 0.05% Tween were serially diluted threefold in microtiter plates. 
» The plates were incubated at 37°C for 90 minutes. 
» The plates were washed 3 times with PBS-Tween (0.05 %) and once with PBS. 
» The horseradish peroxidase (HRP) conjugated rabbit anti-human IgA and IgG were 
diluted in 0.1 % BSA-PBS Tween and I 00 ~I was added to each well. 
• Anti-human IgA HRP (e.g. Jackson 309035011 , 111000) 
• Anti-human IgG HRP (e.g. Jackson 309035006, 1/1000) 
» The plates were incuhated for 90 minutes at 3~C . 
» The plates were washed 3 times with PBS- Tween (0.05 %) and once with PBS. 
» The plates were developed with the substrate orthophenylene diamine (OPD) as 100~1 / 
well, prepared by dissolving 10 mg ofOPD in 10 ml of 0.1 M sodium citrate buffer, (pH 
4.5) to which was added 4 ~I of 0.1 % H2Ch immediately before use. 
» The plates were read kinetically at 450 nm for five minutes. The maximal rate of change 
in optical density in milli absorbance units per minute was normalized across plates by 
calculating the ratio of the test sample to a standard of pooled convalescent-phase serum 
from previously-infected cholera patients, which was added as a positive control on each 
plate. For the LPS antigen, individuals with a ~-fold increase in antibody titer one or 
three weeks post infection or vaccination were considered as responders. 
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4.6 Vibriocidal Antibody Assay 
2: 2 
Vibriocidal antibody assays were performed USIng gUinea pig complement and with V. 
cholerae 01 Ogawa (X-25049) as the target organism. Vibriocidal titer was defined as the 
reciprocal of the highest dilution resulting in >50% reduction of the optical density when 
compared to that of control wells without serum. Individuals showing a 2:4-fold increase in 
vibriocidal responses one or three weeks post infection or vaccination were considered 
responders. 
Procedure: 
~ V. cholerae 01 (strain 19479 EI Tor. lnaba) were cultured overnight on blood agar plates 
at 31'C. 
~ A loopful of bacteria from the plates was inoculated in 15 ml BlIT (brain-heart infusion)-
medium in a conical flask with cotton plug. This was incubated on a shaker at 31'C for 
3-4 hours. 
~ The culture was centrifuged at 3000rpm for 10 minutes and the supernatant was thrown 
away. The sediment was resuspended in sterile saline. 
~ This was again centrifuged for another 8-10 minutes. The pellet was resuspended In 
sterile saline. 
~ Bacterial concentration was adjusted by spectrophotometer at 600 nm. For V. cholerae 
01 OD was adjusted at 0.3 
~ Heat-inactivated (560 C, 30 minutes) sera was diluted 2-fold In sterile saline In flat-
bottom microtiter plates (Nunc, F) as follows : 
• 25 fil of cold saline was dispensed in all wells except column #2. 
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equals to I : 1 0240). The last 25 III was discarded from the last well on each row. The 
plates were kept at 4°C (on ice) until used. 
}> The indicator (bacteria-complement-saline mixture) was prepared. The composition for 
each plates is as follows : 
Sterile Saline Bacteria Complement 
V. cholerae 01 (X25049 and 19479) 2.55 rnI 
}> The indicator was used immediately after preparation. 
}> 25 III of the indicator was added to all wells except wells in row A, B, C and D in column 
#1. The plate was incubated on a shaker at 3rC for 1 hour (50 revolutions Imin). 
}> 150 III BIll was added to each well. This was incubated for another 3-4 hours at 37°C 
without shaking. The plates were read visually and spectrophotometrically. The 
absorbance for control wells should reach 0.20 to 0.28 at 595 nm. 
Vibriocidal antibody titer is defined as the reciprocal of the highest serum dilution resulting 
in greater than 50% OD reduction when compared to the OD of control wells without serum. 
4.7 Data analysis 
Comparisons of immunologic responses were tested for significance within groups using the 
Wilcoxon Signed Rank test, among the groups using Mann Whitney Rank-sum test and for 
responder frequency comparison among different groups, we used chi-square test. All 
reported P values are two-tailed, with a cutoff of P ~ 0.05 considered a threshold for 
statistical significance. Analyses were performed on GraphPad Prism 4.0 and SigmaStat 3.1. 
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responses of the children, data were also collected from 32 adults (18-45 years) vaccinees 
from the earlier studies [18]. The demographic characteristics of the study participants are 
presented in Table I . 
Table 3.1: Demographic and serologic characteristics of the pediatric study 
participants 
Characteristics 
Median age (years) 
No. of subjects in Sex groups 
Male 
Female 
No. of subjects with blood groups 
o 
A 
B 
AB 
2-5 years 
(N=20) 
4.75 
11 
9 
9 
5 
4 
2 
6-17 years 
(N=20) 
10.55 
10 
\0 
7 
4 
6 
3 
18-45 years 
(N=32) 
33 
13 
19 
12 
7 
II 
2 
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Sludyday ~ ,;" tt #' ",,~ If> ,," tt #' "" .. <> If> ,," tt #' ,;. . " 
Fold Increase 22.6 6.3 1.5 1.5 42.3 6.9 2.3 1.2 34.7 5A 3.5 6.1 
Response(% ) 65 39 11 18 90 .., 21 11 83 38 37 34 
2-5 years cohort 6-17 years cohort 16-45 years cohort 
.Figure-3.t: Vibriocidal responses among vaccinees of different age groups. The 
columns indicate mean reciprocal end titers; error bars represent the standard errors of the 
mean. The Wilcoxson signed-rank test was used for the analysis of data. An asteric indicates 
a statistically significant difference (P<O.OS) from the baseline preimmune response. Mean 
fold changes and responder frequencies are also listed. 
After vaccination, most of the study participants mounted strong vibriocidal responses. The 
vibriocidal response was represented by a ~4-fold increase in immunoglobulin titer 
compared to baseline. 42.3-fold increased vibriocidal titer was observed in older children 
vaccinees on day 3 compared to baseline. The highest fold increase in vibriocidal titer in 
younger children at day 3 was 22.6 and in adults was 34.7. 
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0.0001), older children (GM= 452.54, 95% CI=430.5 to 1124, P= 0.0001) and in adults 
(GM= 305.5, 95% CI= 333.2 to 1300, P<O.OOOI). 
For the adu lt vaccinees, the antibody titers remained significantly elevated up to day 180 
(P= 0.007). On the other hand, the antibody titers remained significantly elevated up to day 
30 for both young and older children, and subsequently declined to baseline. The vibriocidal 
responder frequency and magnitude of responses were comparable in both one and two dose 
vaccine cohorts in the respective days. 
3. Plasma anti-CT and anti-LPS specific antibody responses 
Plasma CT-specific IgA and IgG levels and LPS-specific IgA and IgG levels were measured 
at days 0, 3, 30, 90 and 180. 
3.1 Anti-CT IgA responses 
After vaccination, plasma CT or LPS specific antibody responses were determined by a 
twofold or greater increase of antibody titer from the baseline. In 2-5 years cohort, 100% 
vaccinees were shown to mount strong CT-specific plasma IgA responses with 13.1 fold 
increased in immunoglobulin titer at day 3 (Figure 3.2). The most promising CT-specific 
plasma IgA responses were observed at day 3 in the 6-17 years old cohort, where 90% 
vaccines mounted 21.1- fold increased antibody titer. Strong CT -specific plasma IgA 
responses were also observed at day 3 in 97% adult vaccinees with a 15.4 fold increased 
antibody titer. 
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[n younger and older children, these responses remained elevated up to day 30 and returned 
to baseline by day 90. In case of adult vaccinees, CT -specific [gA responses persisted up to 
day 90. No significant di fference was observed in CT-specific JgA responses among the 
different age groups vaccine recipients in the corresponding study days. 
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Study day dO d3 d30 d90dl80 dO d3 d30d90dl80 dO d3 d30d90d180 
Fold increase 13.1 3.3 1.3 1 21.1 4.4 1.8 1 15.4 4.3 2.8 3.9 
Response(% ) 100 78 33 18 90 80 32 11 97 70 47 38 
2-5 years cohort 6-17 years cohort 18-45 years cohort 
Figure-3.2: Mean normalized plasma CT-specific IgA antibody responses with (± 
SEM) standard error bars. The Wi lcoxson signed-rank test was used for the analysis of 
data. An asteric indicates a statistically signi ficant difference (P<O.OS) from the baseline 
preimmune response. Mean fo ld changes and responder frequencies are also listed. 
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of vaccinees with 4.2-fold increased immunoglobulin titer. On the other hand, highest fold 
increase of6.7 for CT-specific IgG was found in 91% adult vaccinees at day 3. 
Anti-CT specific IgG responses were statistically significant at day 3 in younger (GM= 
66.45; 95% CI= 55.74 to 77.16; P= 0.0005), and it remained significantly elevated up to day 
90. On the other hand, in older children significant anti-CT specific IgG responses were 
found at day 3 (GM= 81.70; 95% CI= 70.70 to 92.70; P= <0.0001), which remained 
significantly elevated up to day 30. In case of adult vaccinees, significantly increased CT-
specific IgG responses were found at day 3 (GM= 64.45; 95% CI= 54.39 to 74.52; P= < 
0.0001), and the responses remained significantly higher up to day 180. 
Statistically significant differences in anti-CT specific IgG responses were found among all 
3 age groups of vaccinees. Compared to younger children and adult vaccinees, anti-CT 
specific IgG responses were higher in older children vaccinees at day 30 (P= < 0.0001). 
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R c sponse(%) 95 81 44 31 90 90 25 18 91 85 3.9 61 
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Figure-3.3: Mean normalized plasma CT-specific IgG antibody responses witb (± 
SEM) standard error bars. The Wilcoxson signed-rank test was used for the analysis of 
data. An asteric indicates a statistically significant difference (P<0.05) from the baseline 
preimmune response. Mean fold changes and responder frequencies are also listed. 
3.3 Anti-LPS IgA responses in vaccinees 
In the adult age groups, 69"10 vaccinees shown to have strong LPS-specific IgA responses 
with 5-fold increased immunoglobulin titer at day 3. On the other hand, 60% younger and 
50% older pediatric vaccinees mounted strong LPS-specific IgA responses at day 7 with 4-
fold and 3.7-fold increased immunoglobulin titer, respectively (Figure 3.4). 
LPS-specific IgA responses were significantly elevated at day 3 both in younger (GM= 
22.00; 95% CI= 11.92 to 32.08; P= 0.0004) and older children (GM= 20.65; 95% CI= 12.26 
to 29.04; P= 0.0005) vaccinees. The highest statistically significant LPS-specific IgA 
responses were found early in adult vaccinees at day 3 with GM= 35.93; 95% CI= 21.09 to 
50.77; P= < 0.0001. 
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recipients in the corresponding study days. 
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Study day dO d3 d30 d90dl80 dO d3 d30 d90dl80 dO d3 d30 d90d180 
Fold increase 
Re,poD.e(~.) 
4 1.17 0.7 0.6 
60 17 6 0 
2-5 years cohort 
3.7 1 0.8 0.6 
50 5 5 6 
6-17 years cohort 
5 1.3 1.3 1.4 
69 13 13 19 
18-45 years cohort 
Figure-3.4: Mean normalized plasma LPS-specific 19A antibody responses with (± 
SEM) standard error bars. The Wilcoxson signed-rank test was used for the analysis of 
data. An asteric indicates a statistically significant difference (P<O.05) from the baseline 
preirnmune response. Mean fold changes and responder frequencies are also listed. 
3.4 Anti-LPS IgG responses 
Anti-LPS JgG responses in all 3 age groups were lower than anti-CT specific IgG. The 
response frequencies at day 3 were 19% with 1.6-fold increased antibody titer in younger 
child vaccinees and in older child vaccinees it was 40% with 2-fold increased antibody titer 
(Figure 3.5). The highest anti-LPS IgG responses of 3.6-fo1d increased were found in 56% 
adult vaccinees. 
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In case of younger child vaccinees, the significant level of anti-LPS specific IgG responses 
was found at day 3, and which returned to baseline by day 30. In case of both older child and 
adult vaccinees, significant level of anti-LPS specific IgG responses were found at 3, which 
remained elevated up to day 30 before declining to baseline by day 90. No significant 
difference was observed in CT -specific IgA responses among the different age groups 
vaccine recipients in the corresponding study days. 
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Figure-3.5: Mean normalized plasma LPS-specific IgG antibody responses with (± 
SEM) standard error bars. The Wilcoxson signed-rank test was used for the analysis of 
data. An asteric indicates a statistically significant difference (P<O.OS) from the baseline 
preimmune response. Mean fold changes and responder frequencies are also listed. 
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0, 30, YO, and IlSU. Atter SIX day PtsMC culture In L'I well culture plateS, uruy L!lUSe lIlal 
showed stimulation of PBMC as a ~4-fold increase in the number of total immunoglobulin 
memory cells following stimulation, compared to unstimulated cells, were considered for 
analysis. 
4.1 CT-specific 19A aDd IgG Memory B-cells 
Statistically significant increases in anti-CT -specific IgA memory B-cell responses were 
observed only for adult vaccinees. CT -specific IgA memory B-cell responses increased on 
day 30 (P =0.001) and persisted up to day 90 (P= 0.01 95) and after that these responses 
returned to baseline by day 180 (Figure 3.6). 
In young and older children vaccinees, CT specific IgA memory B-cell responses increased 
up to day 90. However, there was no significant memory B-cell response for the both 
younger and older children vaccinees. No significant difference was observed in CtxB-
specific IgA memory B-cell responses among the different age groups vaccine recipients in 
the corresponding study days. 
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Figure-3.6: Mean CTB-specific JgA memory B-cells responses in different age groups. 
The columns indicate mean reciprocal end titers; error bars represent the standard errors of 
the mean. The Wilcoxson signed-rank test was used for the analysis of data. An asteric 
indicates a statistically significant difference (P<0.05) from the baseline prelmmune 
response. Mean fold changes and responder frequencies are also listed. 
Similarly, in adult vaccinees significant increases in anti-CT specific IgG memory 8-cell 
responses were observed at day 30 (P= 0.006), and which remained elevated up to day 90 
(P= 0.008) and subsequently these responses returned to baseline by day 180 (Figure 3.7). In 
case of both younger and older child vaccinees, there was no significant level ofCT-specific 
IgG memory B-cel l responses, but the response was tended to be higher at day 30 (P= 
0.0625). 
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Figure-3.7: Mean CTB-specific IgG memory B-cells responses in different age groups. 
The columns indicate mean reciprocal end titers; error bars represent the standard errors of 
the mean. The Wilcoxson signed-rank test was used for the analysis of data. An asteric 
indicates a statistically significant difference (P<O.OS) from the baseline preimmune 
response. Mean fold changes and responder frequencies are also listed. 
4.2 LPS-specific JgA and IgG Memory B-cells 
LPS-specific memory B-cell responses are shown in figures 3.8 and 3.9. LPS-specific IgA 
memory B-cell responses were comparatively higher than CT -specific IgA memory B-celJ. 
However, no significant increase of LPS-specific IgA memory B-cell responses was 
observed in any age group ofvaccinees. In addition, there was no difference in LPS-specific 
IgA memory B-cell responses among vaccinees in any corresponding study days too. 
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Figure 3.8: Mean LPS-specific IgA memory B-cells responses in different age groups. 
LPS-specific JgG memory B-cell response is comparatively lower than CtxB-specific JgG 
memory B-cell. No significant increase of LPS-specific IgG memory B-cell responses was 
observed in any age group of vaccines and there was no difference in LPS-specific JgG 
memory B-cell responses among vaccinees in any corresponding study days too. 
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Figure 3.9: Mean LPS-specific IgG memory B-cells responses in different age groups. 
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cell killed cholera vaccine now available in many countries including Bangladesh [159). In 
addition to recombinant cholera toxin B-subunit, this vaccine also contains inactivated 
whole-cell cholera vibrios and has been registered in more than 60 countries worldwide 
[75). 
One important observation in immune response against WC-rCTB (Dukoral) is that the level 
of vaccine-induced protection is age-dependant, being lowest in young children (a 
population group which is at high risk of cholera), and highest in adults, indicating that 
vaccines worked best in immunologically-primed populations by boosting underlying 
immunity. In adults and children above age 5 yr, protection remains at or above 60 per cent 
for another 2-3 yr. In children below age 5, the vaccine induces very high short-term 
efficacy (100% for the first 4-6 months) mediated by locally produced 19A antitoxic 
antibodies, but in this age group protection waned more rapidly than that in older children 
[160). 
The ultimate goal of all vaccination strategy is to generate effective long-term memory. The 
persistence of memory B cells is of utmost importance for long-term vaccine efficacy. 
Memory B-cell responses, defined as rapid induction of high levels of high affinity antibody 
after secondary antigen challenge, are characterized by production of JgG and JgA 
antibodies, and by somatic mutations in the antigen-binding domains of the heavy and light 
chains of these antibodies [161). Current understanding of memory B cell generation 
suggests that antigens such as CT lead to the activation and proliferation of naive B cells in 
a CD4 T cell-mediated fashion. Activated B-cells may then differentiate into short-lived, 
antigen-committed ASCs or undergo a germinal center reaction with CD4 T cell help, where 
somatic hypermutation, atTmity maturation, and class switching generate high-affinity, 
antigen-specific memory B cells. Memory B-cells can persist for decades in an antigen-
independent manner and can be further boosted by subsequent antigenic exposure [103, 
162). 
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recipients. The vaccinees were divided into three age groups; young children (2-5 years), 
older chi ldren (6-17 years), and adults (18-45 years). The memory 8 -cell responses of these 
cohorts were also compared against one another. 
In this study, a significant level of CT -specific IgA memory B-cell responses was found in 
adult vaccine participants. The increased responses were observed after one month of 
vaccination (P =0.001) and persisted up to three months (P= 0.0195) (Fig. 3.6). After that, 
CT-specific IgA memory 8-cell responses returned to baseline by day 180. However, 
significant level ofCT-specific IgA memory B-cell responses were found up to day 270 in 
naturally infected cholera patients in the earlier study [18]. On the other hand, CT-specific 
IgA memory B-cell responses in both younger and older child vaccinees were not that 
significant compared to adult vaccines after one month of vaccination, and these short-lived 
responses wane down to baseline on the subsequent days (Fig. 3.6). These findings are 
comparable with child patients naturally infected with V. choleare, as shown recently [163]. 
Both of these groups of vaccinees and naturally infected patients showed relatively short-
lived CT-specific IgA memory 8-cell responses. 
Moreover, significant level of CT -specific IgG memory 8-cell responses was found at day 
30 (P= 0.006) in adult vaccine participants, and these responses remained elevated up to 
three months (P= 0.008) (Fig. 3.7). In case of both younger and older child vaccinees, there 
was no significant level of CT -specific IgG memory 8-cell responses, but the response was 
tended to be higher at day 30 (P=0 .0625) (Fig. 3.7). Present study reflects that the CT-
specific IgG memory B-cell responses in adult vaccinees are comparable up to day 180 to 
those found in the naturally infected adult patients [18]. In older child vaccinees, comparable 
responses were found to those of naturally infected cholera patients [163]. However, 
significant differences were observed in the younger children group of vaccinees and 
cholera patients; naturally infected patients shown to have elevated level of CT -specific IgG 
memory B-cell responses at day 30 [163] compared to vaccinees. 
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carbohydrate antigen, responses to LPS is T-cell independent [164]. On the contrary, 
memory 8-cell response to protein antigen (e.g. CT) is dependent on T-cell responses [165]. 
Cytokine secretion and co-stimulation by CD4+ T-cell are the primary determinants of the 
quality and duration of memory B-cell responses to protein antigen like CT. The direct 
binding of T-cell and B- cell in secondary lymphoid tissue facilitates CD40 and CD40L 
interaction which is critical for 8-cell proliferation and isotype switching [164] . Hence, the 
stability to memory B-cell responses after exposure to CTB, in contrast to T-cell 
independent antigens such as LPS, is likely the result of T-cell contributions to memory B-
cell activation (166]. 
The vibriocidal antibody response is one of the most commonly used markers for assessing 
protection against cholera. It is thought to be a surrogate marker of protection since it detects 
the presence of complement binding anti-V. cholerae antibodies in the peripheral blood. 
However, there is no known vibriocidal titer above which protection is complete (12], and 
vibriocidal antibody levels fall to baseline within several months after infection [26]. In 
areas of the world in which cholera is endemic, the mean vibriocidal antibody titer increases 
with increasing age, presumably reflecting previous exposure to V. cholerae (16]. 
In the present study, it has been found that child vaccinees developed significantly higher 
magnitude ofvibriocidal antibody titers at days 21 and adults at day 17 (Fig. 3.1). In case of 
both groups of child vaccinees, these responses remained elevated up to day 30, and which 
returned to baseline by day 90. On the other hand, in adult vaccinees, elevated level of 
vibriocidal antibody titers were found throughout the study period of 6 months (Fig. 3.1). 
These results are consistent to earlier studies (18, 163]. Moreover, vibriocidal antibody 
responses in adults are comparable to the naturally infected cholera patients [18]. In the 
present study, it was found that young children had the lowest baseline vibriocidal antibody 
levels, presumably a reflection of the fact that older children and adults might have already 
been exposed to V. cholerae infections. Despite this, the magnitudes of the vibriocidal 
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and persisted up to I month in both groups of child vaccinees (Fig. 3.2). On the other hand, 
relatively long-lived CT specific plasma IgG responses were seen in younger child 
vaccinees than the older children, presumably reflecting that the younger children were 
recently exposed to V. cholera (Fig. 3.3). These responses were even longer in case of adult 
vaccinees; up to 3 months for 19A (Fig. 3.2) and 6 months for IgG (Fig. 3.3). Significant 
level of LPS-specific IgA was found only at day 7 in both groups of child vaccinees, 
whereas in adult it remained elevated up to I month (Fig. 3.4). On the other hand, significant 
increase in LPS-specific IgG was found at day 7 in younger child vaccinees, but it persisted 
up to day 30 in both older child and adult vaccine participants (Fig. 3.5). These findings 
support that antibody responses persist for longer period to protein antigens like CT than to 
non-protein antigens (LPS). 
From this study it was shown that administration of oral cholera vaccine developed strong 
memory B-cell responses in adult vaccine participants. This might be due to the fact that 
adults are earlier exposed to V. choleare and have the efficient and robust immune systems 
than the children. However, the memory B-cells responses in adult vaccinees diminished 
after 3 months of vaccination. In older child vaccinees these responses tended to be higher 
than the younger children, but were not that significant to render immune protection against 
V. cholerae. This present study shows some degree of anamnestic recall, but this protective 
efficacy rapidly falls after oral cholera vaccination by WC-rBS. [167]. Comparing the 
present data with the previous data it can be said that vaccine is playing a protective role but 
it is not as efficient as the protection provided by the natural cholera infection. 
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APPENDICES 
1. Eppendorf tubes and micropipette tips were taken from Eppendo~ and Sigma, 
and were sterilized by autoclaving at 121 °C for 20 minutes. 
2. Petri dishes used in the experiments were provided by either Sterilin or Gibco. 
Screw capped tubes and other glass wares were taken from Pyrex~ Labware, USA. 
3. Plastic tubes and pipettes were of Falcon~; both were the brands of Becton, 
Dickinson and Company. 96-weU ELISA plates were obtained from Nunc~, Sweden. 
4. Micropipettes were from Thermo Labsysterns. 
5. Mini scale centrifugations were carried out in a Sorvall~ piCD microfuge and 
large-scale centrifugation were carried out in a Sorvall~ Legend no XRT super speed 
centrifuge. ELISA reading was taken using ASCENT Multiskan~ reader. 
6. Heparin-coated sterile vacutainer tubes (Becton Dickinson, Ruther-ford, NJ) 
7. Multi-channel dispenser (Lab System, USA) 
Chemicals/Reagents: 
1. Acetic acid, Sigma-758-12-3 
2. AEC: Amino ethyl carbazole, Sigma, A-5754 
3. BCIP (5-Brom0-4-Chloro-3-lndolyl Phosphate, Para Toludine Salt) - Sigma, 
B8503 
4. DMF (N, N-Dimethyl-Formamide), Sigma, 0-8654 
5. FBS (Foetal Bovine Serum Albumin), Gibco BRL-16140-071 
6. Ficoll , Pharmacia LKB Biotechnology AB Uppsala, Sweden. 
7. Goat anti human IgG F(abh, Jackson lmmuno Research 109-005-097 
8. Goat anti-human IgA-HRP, Southern Biotechnology Associates, Inc. 2050-05 
9. Goat anti-human IgG-AP, Southern Biotechnology Associates, Inc. 2040-04 
10. H2<h (Hydrogen Peroxide), Fisher Scientific, H-325 
II . MgCh (Magnesium chloride), Sigma- 7786-30-3 
16. KH2PO. (potassium Phosphate) 
APPENDIXB 
Buffers and Substrate Solutions 
1. Preparation of phosphate butTered saline (PBS) (Vacutainer System; Becton 
Dickiuson, Rutherford, NJ) (pH 7.2) 
NaCI (0.136mM Fischer Scientific, Pittsburgh, P A, USA)--------------80.00g 
Na2HP04--
KH2P04 __ _ 
_ ____ _ _ _____ 27.50g 
____ ___ 2 .75 g 
KCL (Fischer Scientific, Pittsburgh, PA, USA)----------------------2.oo g 
Deionized water ·----------------------·---------------------1000.0 ml 
The concentrated solution (I OxPBS) was diluted ten times and was used as working 
solution. 
2. Preparation of 0.05% PBS-Tween (lOOOml) 
Tween -·----·-·----------------------------------·--------0.5ml 
PBS -------------------------------------------.---.. ---.-I Oooml 
3. Preparation of 1 % BSA in PBS (500 mI) 
Phosphate Buffer Saline (PBS) ---·----------------------·-----------500 ml 
Bovine Serum Albumin (BSA) -------- ·------------------------5 g 
4. Preparation of 1 % BSA in PBS-Tween (500 mI) 
Phosphate Buffer Saline (PBS) ----------------------------------·-500 ml 
Bovine Serum Albumin (BSA) ·----------------- -------------------0.5 g 
Tween --------------------------------------------- -------250 f.l.1 
II 
Phosphate Buffer Saline (PBS) --------------------------------500 mJ 
Bovine Serum Albumin (BSA) -------------------------------0.5 g 
Tween-----------------------------------------------------250 f1I 
7. PI'l~paration of Sodium citrate buffer (pH 4.5) (tOOOml) 
Tri-natrium citrate (Na,C6H,0 •. 2H20) --------------------------29.4 g 
H20 (deionized) ---------------------------------------1000.0 mJ 
8. Preparation of Orthophenylene diamine - H20 2 substrate (10 m1) 
° PD------------------------------------------------------------1 0.0 mg 
0.1 M sodium citrate (pH 4.5) - --------- ----------------------10.0 mJ 
30% H2~ --------------------------------------------4.0 ~l 
9. Preparation of 1 % FBS in PBS-Tween (500 ml) 
Phosphate Buffer Saline (PBS) ---------------------------------500mJ 
Fetal Bovine Serum (FBS) ----------------------------------5.0 mJ 
Tween --------------------------------------------------250 f1I 
10. Preparation of BCIP (4m1) 
DMF-----------------------------------------------------4mJ 
BCl.P--------------------------------------------------60mg 
n. Preparation of NBT (4m1) 
70% 0 MF ----------------------------------------------------4mJ 
NBT -----------------------------------------------------120mg 
111 
Deionized water ---------------------------- ----------------- J uwrru 
13. Preparation of ALP chromogen/substrate: BCIPINBT 50ml 
BCIP (60 mg!4 mI 100% DMF) ----------------------------0.5 mJ 
NBT (120 mg!4 m170% DMF 
[2.8m! DMF+ 1.2m! dH20])------------------------------------O.5 m! 
Carbonate Buffer -----------------------------------------50 m! 
14. Preparation ofHRP chromogen /substrate: AEC/H2~ 10ml 
AEC -------------------------------------------------------10 mg 
Dimethyl formarnide (DMF) --------- -------------------------1 mJ 
The mixture is then dissolved in 30mL of 0.1 M sodium acetate buffer (16.4 g ofO.2M 
Na-acetate dissolved in 1000 m! of distilled water, and then the pH was adjusted to 
5.0 with 0.2 M acetic acid). The AEC solution was filtered through 0.2/IDl Millipore 
filter and stored in a 50 mI plastic tube wrapped with aluminium foil. Stable at 4° C 
for a week. 
15. Preparation of tl)'pban blue (l00ml) 
NaCI -------------------------- --------------------------0.8Ig 
___ _ _ _ 0.06g 
Tryphan blue---------------------------------------------O.4g 
Deionized water-------------------------------------------IOO.Om! 
APPENDIXC 
Media 
1. Preparation of RPM] complete medium (220 ml) 
RPMl 1640 ( I X) -------------------------------------------200 ml 
Fetal Bovine Serum (FBS- 10%) ----------------------------20 ml 
IV 
2. Preparation of RPMI- MBCS (Basic Culture Media) (220 ml) 
RPMl 1640 (I X) ------------------------------------------200 mI 
Fetal Bovine Serum (FBS- 10%) ---------------------------20 mI 
PcnlStrp (penicilLin-Streptomycin- 2%) ----------------------4m1 
L- Glutamine (1 %) ---------------------------------------2m1 
~- mercaptoethanol (I : 1000 dilution) ---------------------- 20~ 
3. Preparation of Stimulation media (20 mJ) 
Basic Culture Media -----------------------------------------20 mI 
Pokeweed mitogen (pWM - 1 %) ----------------------------------20 111 
Staphylococcus aureus Cowan (SAC - 0.1 %) -------------------------2.0!J.I 
CpG (6%) --------------------------------------------------120.O!J.I 
4. Preparation of BID media (lOOOml) 
BHI -------------------------------------------------------37. Og 
Deionized water---------------------------------------------I OOOrn! 
5.Pl'eparation of TIGA culture media 
Composition ofTIGA: 
Reagent Amount 
Trypticase (Casein) (BD) ... ...... ... ... ... ... ...... ...... ... ... .. . ........ . . 109 
Nacl (BDWMERCK).............. . ..... . ......... ........ ....... ..... ... .... 10 g 
Sodium taurocholate (Sigma)... ... .. . ...... ..... . ... ... ... ... ... ........... 5g 
Sodium carbonate (Sigma)...... ... .. .... .. ................................ 1.2-l.5g 
Gelatin (BDH) ... ... ... ... ... .. . ... .. . ... ... .. . ... ... ... ... ... ... ... ... ... ... . 30g 
Agar (BD) .. . ... ........ ........ .................... ...... ...... ......... 16g 
v 
tjelOrt~ pounng Ul~ VI(U~S \,:Ui1I auuOl JV \.... , auu VVl4:);:)lUJIl lCllW U\.. 
(K2 Te03)(5uglml). 
APPENDIXD 
Softwares: 
1. MSwoni 
2. Microsoft Excel! 
3. GraphPad Prisom (Graph PAD Software, 2236 Avenidade la Playa, 
La Jolla, CA 92037, USA) 
4. Endnote X 
VI 
REFERENCES 
Bangladesh. J Lnfect UIS, 2UU2. 1116(2): p. 240-) L 
4. Ryan, E.T. , et aI ., Mortality. morbidity, and microbiology of endemic cholera among 
hospitalized patients in Dhaka. Bangladesh. Am 1 Trop Med Hyg, 2000. 63(1-2): p. 12-
20. 
5. Chowdhury, F. , et aI ., A comparison of clinical and immunologic features in children and 
older patients hospitalized with severe cholera in Bangladesh. Pediatr Infect Dis 1, 2008. 
27(11): p. 986-92. 
6. Kanungo, S., et aI ., Immune responses following one and two doses of the reformulated, 
bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, 
India: a randomized, placebo-controlled trial. Vaccine, 2009. 27(49): p. 6887-93 . 
7. Harris, lB., et aI., Cholera's westernfront. Lancet, 2010. 376(9757): p. 1961-5. 
8. Cholera: global surveillance summary, 2008. WkJy Epidemiol Rec, 2009. 84(31): p. 309-
24. 
9. Harris, J.B., et aI., Immunologic responses to Vibrio cholerae in patiellls co-infected with 
intestinal parasites in Bangladesh. PLoS Negl Trop Dis, 2009. 3(3): p. e403 . 
10. Hoque, M.A., et aI ., Monitoring the health and production of household Jinding ducks on 
Hatia Island of Bangladesh. Trop Anim Health Prod, 2011 . 43(2): p. 431-40. 
11 . Koelle, K., et aI ., Refractory periods and climate forcing in cholera dynamics. Nature, 
2005 . 436(7051): p. 696-700. 
12. Saba, D. , et aI ., Incomplete co"elation of serum vibriocidal antibody tiler with protection 
from Vibrio cholerae infection in urban Bangladesh. 1 Infect Dis, 2004. 189(12): p. 2318-
22. 
13 . Clements, M.L. , et aI. , Magnitude, kinetics, and duration of vibriocidal antibody 
responses in North Americans after ingestion of Vibrio cholerae. J Infect Dis, 1982. 
145(4): p. 465-73 . 
14. Asaduzzaman, M., et aI., The major subunit of the toxin-coregulated pilus TcpA induces 
mucosal and systemic immunoglobulin A immune responses in patients with cholera 
caused by Vibrio cholerae 01 and 0139. Infect Imrnun, 2004. 72(8): p. 4448-54. 
15 . Harris, I .B., et aI., Susceptibility to Vibrio cholerae infection in a cohort of hmlsehold 
contacts of patients with cholera in Bangladesh. PLoS Neg) Trop Dis, 2008. 2(4): p. e221 . 
6Sl Page 
18. A1am, M.M., et al ., Antigen-specific memory B-cell responses in Bangladeshi adults ajler 
one- or two-dose oral killed cholera vaccination and comparison with responses in 
patients with naturally acquired cholera. Clin Vaccine Immunol, 20 II . IS(5): p. 844-50. 
19. Mahalanabis, D ., et al., A randomized, placebo-controlled trial of the bivalent killed, 
whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in 
Kolkata, India. PLoS One, 2008. 3(6): p. e2323 . 
20. Trach, D.D., et al ., Investigations into the safety and immunogenicity of a killed oral 
cholera vaccine developed in Viet Nam. Bull World Health Organ, 2002. SO(I): p. 2-8 . 
21. Ryan, E.T. and S.B. Calderwood, Cholera vaccines. Clin Infect Dis, 2000. 31(2): p. 561-
5. 
22. Ryan, E.T., S.B. Calderwood, and F. Qadri, Live attenuated oral cholera vaccines. Expert 
Rev Vaccines, 2006. 5(4): p. 483-94. 
23 . Sur, D., et al ., Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in 
India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. 
Lancet, 2009. 374(9702): p. 1694-702. 
24. Legros, D. , et al ., Mass vaccination with a two-dose oral cholera vaccine in a refugee 
camp. Bull World Health Organ, 1999. 77(10): p. 837-42. 
25 . Kelly, D.F., A.J. Pollard, and E.R. Moxon, ImmunolOgical memory: the role of B cells in 
long-term protection against invasive bacterial pathogens. JAMA, 2005. 294(23): p. 
3019-23 . 
26. Harris, A.M ., et al ., Antigen-specific memory B-cell responses to Vibrio cholerae OJ 
infection in Bangladesh. Wect Immun, 2009. 77(9): p. 3850-6. 
27. Sack, D.A., R.B. Sack, and C.L. Chaignat, Getting serious about cholera. N Engl J Med, 
2006. 355(7): p. 649-51. 
28. Cholera vaccines: WHO position paper-Recommendations. Vaccine, 2010. 2S(30): p. 
4687-8. 
29. Mason, P.R., Zimbabwe experiences the worst epidemic of cholera in Africa. J Infect Dev 
Ctries, 2009. 3(2): p. 148-5\. 
30. Chin, C.S., et al ., The origin of the Haitian cholera outbreak strain. N Engl J Moo, 2011 . 
364(1): p. 33-42. 
661 Page 
33 . Glass, R.I., et aI., Endemic cholera in rural lJangJaaesn, lYOO-l:;lOV. ~J1 J '-' .... U""'"'V., 
1982. 116(6): p. 959-70. 
34. Stoll, B.J., et aI., Surveillance of patients allending a diarrhoeal disease hospital in 
Bangladesh. Br Med J (Clin Res Ed), 1982.285(6349): p. 1185-8. 
35. Faruque, S.M., et aI., Clonal relationships among classical Vibrio cholerae OJ strains 
isolated between 1961 and 1992 in Bangladesh. J Clin Microbiol, 1993. 31(9): p. 2513-6. 
36. Samadi, A.R , et aI., Classical Vibrio cholerae biotype di~places EL tor in Bangladesh. 
Lancet, 1983. 1(8328): p. 805-7. 
37. Albert, MJ., et aI. , Large olltbreak of clinical cholera dlle to Vibrio cholerae non-OJ in 
Bangladesh. Lancet, 1993 . 341(8846): p. 704. 
38. Large epidemic of cholera-like disease in Bangladesh caused by Vibrio cholerae 0139 
synonym Bengal. Cholera Working Group, IllIernational Centre for Diarrhoeal Diseases 
Research, Bangladesh. Lancet, 1993. 342(8868): p. 387-90. 
39. Siddique, A.K. , et aI. , Emergence of a new epidemic strain of Vibrio cholerae in 
Bangladesh. An epidemiological study. Trop Geogr Med, 1994. 46(3): p. 147-50. 
40. Wittlinger, F., et aI. , Risk of Cholera Among Western and Japanese Travelers. J Travel 
Med, 1995. 2(3): p. 154-158. 
41 . Hill, D.R , L. Ford, and D.G. Lalloo, Oral cholera vaccines: use ill clinical practice. 
Lancet Infect Dis, 2006. 6(6): p. 361-73. 
42. Morger, H., R Steffen, and M. Schar, Epidemiology of cholera in travellers, and 
conclusions for vaccination recommendations. Br Med J (Clin Res Ed), 1983. 286(6360): 
p. 184-6. 
43 . Koch, R , An Address 011 Cholera and its Bacillus. Br Med J, 1884. 2(1236): p. 453-9. 
44. Gardner, A.D. and K. V. Venkatraman, The Antigens of the Cholera Group of Vibrios. J 
Hyg (Lond), 1935. 35(2): p. 262-82. 
45 . Ramamurthy, T. , et aI ., Vintlence pallerns of Vibrio cholerae non-OJ strains isolated 
from hospitalised patients with acute diarrhoea in Calculla, India. J Med Microbiol, 
1993. 39(4): p. 310-7. 
67 I P age 
48. De, S.N ., Enterotoxicity of bacteria·:free cutlure-jl/lrQ/e OJ /IIonu (;flUlt"u~. J""U"', . NJ. 
183(4674) p. 1533-4. 
49. Finkelstein, R.A. and J.J . LoSpaIluto, Pathogenesis of experimental cholera. Preparation 
and isolation of choleragen and choleragenoid. J Exp Med, 1969. 130(1): p. 185-202. 
50. Levine, M.M., et aI ., New knowledge on pathogenesis of bacterial enteric infections as 
applied to vaccine development. Microbiol Rev, 1983. 47(4): p. 510-50. 
51 . Cash, RA., et aI., Response of man to infection with Vibrio cholerae. I. Clinical, 
serologic, and bacteriologic responses to a known inoculum. J Infect Dis, 1974. 129(1): p. 
45-52. 
52. Holmgren, 1. and A.M . Svennerholm, Mechanisms of disease and immunity in cholera: a 
review. J Infect Dis, 1977. 136 Suppl : p. SI05-12. 
53 . King, C.A. and W.E. Van Heyningen, Deactivation of cholera toxin by a sialidase-
resistant monosialosylganglioside. J Infect Dis, 1973. 127(6): p. 639-47. 
54. Pierce, N.F., Differential inhibitory effects of cholera toxoids and ganglioside on the 
enterotoxins of Vibrio cholerae and Escherichia coli. J Exp Med, 1973. 137(4): p. 1009-
23 . 
55 . Moss, J. , et a!., Activation of choleragen by thiol: protein disulfide oxidoreductase. J BioI 
Chern, 1980. 255(23): p. 11085-7. 
56. Bourne, H. R., ADP-Ribosylating Toxins and G Proteins. Insights into Signal 
Transduction Joel Moss and Martha Vaughan, Eds. American Society for Microbiology, 
Washington, DC, 1990. xviii, 567 pp., iIIus. $ 79; to ASM members, $69. Science, 1990. 
250(4982): p. 841-2. 
57. Nikaido, H., Molecular basis of bacterial outer membrane permeability revisited. 
Microbiol Mol BioI Rev, 2003 . 67(4): p. 593-656. 
58. Nikaido, H. , Structure and junctions of the cell envelope of gram-negative bacteria. Rev 
Infect Dis, 1988. 10 Sup pI 2: p. S279-81. 
59. Cabrera, 0 ., et aI ., Preparation and evaluation of vibrio cholerae 01 EL Tor Ogawa 
Iipopolysaccharide-tetamls toxoid conjugates. Vaccine, 2006. 24 Suppl 2: p. S2-74-5. 
60. Kenneth Todar, P., Mechanisms of bacterial pathogenesis -endoloxins Textbook on 
Bacteriology. In. 2008. 
681 Page 
the adjuvant cholera toxin: role of cAMP on chemokine receptor expression. Vaccine, 
2003. 21(9-1O}: p. 856-61. 
63 . Eriksson, K., et a1 ., Cholera toxin and its B subunit promote dendritic cell vaccination 
with different influences on Th1 and Th2 development. Infect Immun, 2003 . 71(4}: p. 
1740-7. 
64. Bromander, A , J. Holmgren, and N. Lycke, Cholera toxin stimulates lL-1 production and 
enhances antigen presentation by macro phages in vitro. J lmmunol, 1991. 146(9}: p. 
2908-14. 
65. Sun, lB., 1. Holmgren, and C. Czerkinsky, Cholera toxin B subunit: an efficient 
transmucosal carrier-delivery system f or induction of peripheral immunological 
tolerance. Proc Nat! Acad Sci USA, 1994. 91(23}: p. 10795-9. 
66. Sun, lB., C. Czerkinsky, and l Holmgren, Mucosally induced immunological tolerance, 
regulatory T cells and the adjuvant effect by cholera toxin B subunit. Scand J Immunol, 
2010. 71(1}: p. 1-11 . 
67. Swerdlow, D.L. and AA Ries, Cholera in the Americas. Guidelines for the clinician. 
JAMA, 1992. 267(11}: p. 1495-9. 
68. Black, R.E., The prophylaxis and therapy of secretory diarrhea. Med Clin North Am, 
1982. 66(3}: p. 611-21. 
69. McCormack, W.M., et a1 ., Tetracycline prophylaxis in families of cholera patients. Bull 
World Health Organ, 1968. 38(5}: p. 787-92. 
70. Roberts, AB., et a1 ., Cholera in the Gilbert Islands. [1. Clinical and laboratory findings. 
Am J Trop Med Hyg, 1979. 28(4}: p. 685-91. 
71. Towner, K.1. , et a1 ., Resistance to antimicrobial agents of Vibrio cholerae E1 Tor strains 
isolated during the f ourth cholera epidemic in the United Republic of Tanzania. Bull 
World Health Organ, 1980. 58(5}: p. 747-51. 
72. Finch, MJ., et ai., Epidemiology of antimicrobial resistant cholera ill Kenya and East 
Africa. Am J Trop Med Hyg, 1988. 39(5}: p. 484-90. 
73 . Levine, M.M., et a1., Duration of infectioll-derived immunity to cholera. J Infect Dis, 
1981. 143(6}: p. 818-20. 
691 Page 
76. Qadri, F. , et aI ., Acute dehydratmg a/sease cal/!leu uy Y IUI/U ~"v ......... J"' V(;' V"Y" ~ . _ •• _ 
0139 induce increases in innate cells and inflammatory mediators at the mucosal surface 
of the gut. Gut, 2004. 53(1): p. 62-9. 
77. Qadri, F., et aI. , Comparison of the vibriocidal antibody response ill cholera due to Vibrio 
cholerae 0139 Bengal with the respanse ill cholera due to Vibrio cholerae 01. Clin Diagn 
Lab Immunol, 1995. 2(6): p. 685-8. 
78. Jertbom, M., A.M. Svennerholm, and J. Holmgren, Intestinal and systemic immune 
responses in humans after oral immunization with a bivalent B subullil-0110139 whole 
cell cholera vaccine. Vaccine, 1996. 14(15): p. 1459-65. 
79. Clemens, J.D., et aI. , B subunit-whole cell and whole cell-only oral vaccines against 
cholera: studies on reactogenicity and immunogenicity. J Infect Dis, 1987. 155(1): p. 79-
85 . 
80. Attridge, S.R. , et aI ., Relative significance of mannose-sensitive hemagglutinin and toxin-
coregulated pili in colonization of infant mice by Vibrio cholerae EI Tor. Infect lmmun, 
1996. 64(8): p. 3369-73. 
81. Tacket, CO., et aI ., Investigation of the roles of toxin-coregulated pili and mannose-
sensitive hemagglutinin pili in the pathogenesis of Vibrio cholerae 0139 infection. Infect 
Immun, 1998. 66(2): p. 692-5. 
82. Jonson, G., J. Sanchez, and A.M. Svennerholm, Expression and detection of different 
biotype-associated cell-bound haemagglutinins of Vibrio cholerae 01. J Gen Microbiol, 
1989. 135(1): p. 111-20. 
83 . Qadri, F., et aI., Immune response to the mannose-sensitive hemagglutinin in patients with 
cholera due to Vibrio cholerae 01 and 00139. Clin Diagn Lab Immunol, 1997. 4(4): p. 
429-34. 
84. Janeway, CA., Jr. , How the immune system protects the host from infection. Microbes 
Infect, 2001. 3(13): p. 1167-71. 
85 . Medzhitov, R. , Recognition of microorganisms and activation of the immune response. 
Nature, 2007. 449(7164): p. 819-26. 
86. Beutler, B., Inferences, questions and passibilities in Toll-like receptor signalling. Nature, 
2004. 430(6996): p. 257-63 . 
70l Page 
IS'!. Kogers, 1'.K., C . uuoey, ana 1> .L. 1>wam, \!uamanve cnanges accompany memory J cell 
generation: faster, more effective responses at lower doses of antigen. J Immunol, 2000. 
164(5): p. 2338-46. 
90. Fazekas de St, G. and R.G. Webster, Disquisitions of Original Antigenic Sill. f. Evidence 
inman. J ExpMed, 1966. 124(3): p. 331-45. 
91. McMichael, A.I. , The original sin of killer T cells. Nature, 1998. 394(6692): p. 421-2. 
92. Fearon, D.T. and RM. Locksley, The instructive role of innate immunity in the acquired 
immune response. Science, 1996. 272(5258): p. 50-3 . 
93 . Zinkemagel, RM., et aI. , Antigen localisation regulates immune responses in a dose- and 
time-dependent fashion: a geographical view of immune reactivity. Immunol Rev, 1997. 
156: p. 199-209. 
94. Janeway, c.A. , Jr. , Approaching the asymptote? Evolution and revolution in immunology. 
Cold SpringHarb Symp Quant Bioi, 1989. 54 Pt 1: p. 1-13. 
95. Medzhitov, R and C.A. Janeway, Jr. , innate immunity: impoct on the adaptive immune 
response. CUff Opin Immunol, 1997. 9(1): p. 4-9. 
96. O'Garra, A. , Cytokines induce the development of fim ctionally heterogeneous T helper cell 
subsets. Immunity, 1998. 8(3): p. 275-83. 
97. Paul, W.E. and R.A. Seder, Lymphocyte respo11Ses and cytokines. Cell, 1994. 76(2): p. 
241-51. 
98. Richter, A., M. Lohning, and A. Radbruch, instruction for cy tokine expression in T helper 
lymphocytes in relation to proliferation and cell cycle progression. J Exp Med, 1999. 
190(10): p. 1439-50. 
99. Reiner, S.L. and RA. Seder, Dealingfrom the evolutionary pawnshop: how lymphocytes 
make decisions. Immunity, 1999. 11(1): p. 1-10. 
100. Slifka, M.K., et aJ ., Humoral immunity due to long-lived plasma cells. Immunity, 1998. 
8(3): p. 363-72. 
101 . Manz, RA., et aI. , Humoral immunity and long-lived plasma cells. Curr Opin Immunol, 
2002. 14(4): p. 517-21. 
71 I P age 
104. Manz, R.A., et a1 ., Survival of long-lived plasma cells is independent of antigen. Int 
Immunol, 1998. 10(11): p. 1703-11. 
105. Lam, KP., R. Kuhn, and K Rajewsky, In vivo ablation of slllface immunoglobulin on 
mature B cells by inducible gene targeting results in rapid cell death. Cell, 1997. 90(6): p. 
1073-83. 
106. van Egmond, M., et aI., IgA and the IgA Fc receptor. Trends lmmunol, 2001. 22(4): p. 
205-11. 
107. Kozlowski, P.A., et a1 ., Comparison of the oral, rectal, and vaginal immunization routes 
for induction of antibodies in rectal and genital tract secretions of women. Infect Immun, 
1997. 65(4): p. 1387-94. 
108. Kozlowski, P.A. , et a1 ., Differential induction of mucosal and systemic antibody responses 
in women after nasal, rectal, or vaginal immunization: irif/uence of the menstrual cycle. J 
Immunol, 2002. 169(1): p. 566-74. 
109. Kaetzel, C.S., et a1 ., The polymeric immunoglobulin receptor (secretory component) 
mediates transport of immune complexes across epithelial cells: a local defense function 
for IgA. Proc Nat! Acad Sci USA, 1991. 88(19): p. 8796-800. 
110. Lamm, M.E., Interaction of antigens and antibodies at mucosal surfaces. Annu Rev 
Microbiol, 1997. 51 : p. 311-40. 
111 . Hutchings, A.B., et a1 ., Secretory immunoglobulin A antibodies against the sigmal outer 
capsid protein of reovinls type I Lang prevent infection of mouse Peyer's patches. J Virol, 
2004. 78(2): p. 947-57. 
112. Robinson, 1.K , et aI. , A mucosal IgA-mediated excretory immune system III vivo. J 
Immunol, 2001. 166(6): p. 3688-92. 
113 . Black, KP., J.E. Cummins, Jr. , and S. Jackson, Serum and secretory IgA from HIV-
infected individuals mediate antibody-dependent cellular cytotoxicity. Clin Immunol 
Immunopathol, 1996. 81(2): p. 182-90. 
114. Eriksson, K. , et a1 ., Specific-antibody-secreting cells in the rectums and genital tracts of 
nonhuman primates following vaccination. Infect lmmun, 1998. 66(12): p. 5889-96. 
115. Brandtzaeg, P., et a1 ., Regional specialization in the mucosal immune system: what 
happens in the microcompartments? Immunol Today, 1999. 20(3): p. 141-51. 
72I Page 
118. Levine, M .M ., Immunization against bacterial diseases of the intestine. J Pediatr 
Gastroenterol Nutr, 2000. 31(4): p. 336-55. 
119. Belshe, R.B., et aI., The efficacy of live allenuated, cold-adapted, trivalent, intranasal 
inJ1uenzavirus vaccine in children. N Engl J Med, 1998. 338(20): p. 1405-12. 
120. Belyakov, I.M. and 1.A. Berzofsky, Immunobiology of mucosal HIV infection and the 
basis for development of a new generation of mucosal AIDS vaccines. Immunity, 2004. 
20(3): p. 247-53 . 
121. Kozlowsk~ P.A. and M.R. Neutra, The role of mucosal immunity in prevention of HIV 
transmission. CUIT Mol Med, 2003 . 3(3): p. 217-28. 
122. Levine, MM., The legacy of Edward Jenner. BMJ, 1996. 312(7040): p. 1177-8. 
123. Whitney, C.G. , et aI., Decline in invasive pneumococcal disease after the introduction of 
protein-polysaccharide conjugate vaccine. N Engl J Med, 2003 . 348(18): p. 1737-46. 
124. Peltola, H., et aI ., Measles, mumps, and rubella in Finland: 25 years of a nationwide 
elimination programme. Lancet Infect Dis, 2008. 8( 12): p. 796-803 . 
125. de Quadros, C.A., et aI., Feasibility of global measles eradication after internlption of 
transmission in the Americas. Expert Rev Vaccines, 2008. 7(3): p. 355-62. 
126. Foege, W.H., J.D. Millar, and J.M. Lane, Selective epidemiologic control in smallpox 
eradication. Am J Epidemiol, 1971. 94(4): p. 311-5. 
127. Henderson, D.A., Principles and lessons from the smallpox eradication programme. Bull 
World Health Organ, 1987. 65(4): p. 535-46. 
128. Black, R.E., et aI ., Global, regional, and national causes of child mortality in 2008: a 
systematic analysis. Lancet, 2010. 375(9730): p. 1969-87. 
129. Adegbola, R.A., et aI. , Elimination of Haemophilus inJ1uenzae type b (Hib) disease from 
The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: 
a prospective study. Lancet, 2005. 366(9480): p. 144-50. 
130. de Palma, 0 ., et aI. , Effectiveness of rotavirus vaccination against childhood diarrhoea in 
El Salvador: case-control study. 8MJ, 2010. 340: p. c2825. 
731 Page 
lJJ . van LOOn, 1' .1:'., et aI. , Neill tT/Ul UJ IIIUt;"Vutt:u Ulut "'"V'~"" .............. " .. , ~w"6.w~~~ .. . 
resultsfrom5yearsoffollow-up. Vaccine, 1996. 14(2): p. 162-6. 
134. Tacket, C.O., et al ., Safety and immunogenicity of live oral cholera vaccine candidate 
CVD 110, a delta ctxA delta zot delta ace derivative of EI Tor Ogawa Vibrio cholerae. J 
Infect Dis, 1993 . 168(6): p. 1536-40. 
135. Levine, M.M., et a!. , Evaluation in humans of attemlOted Vibrio cholerae El Tor Ogawa 
strain Texas Star-SR as a live oral vaccine. [nfect lmmun, 1984. 43(2): p. 515-22. 
136. WHO, G.A.a.R. , Cholera In Pakistan. WHO, Editor, 2010. 
137. Pe1to1a, H., et al ., Prevention of travellers' diarrhoea by oral B-subunit!whole-cell cholera 
vaccine. Lancet, 1991. 338(8778): p. 1285-9. 
138. Lopez-Gigosos, R. , et al ., Effectiveness in prevention of travellers' diarrhoea by an oral 
cholera vaccine WC/rBS. Travel Med Infect Dis, 2007. 5(6): p. 380-4. 
139. Clemens, J.D., et a!., Field trial of oral cholera vaccines in Bangladesh. Lancet, 1986. 
2(8499): p. 124-7. 
140. Clemens, J.D., et al ., Field trial of oral cholera vaccines in Bangladesh: results from 
three-year follow-up. Lancet, 1990. 335(8684): p. 270-3 . 
141. Clemens, J.D., et a!., Cross-protection by B subunit-whole cell cholera vaccine against 
diarrhea associated with heat-labile tOxin-producing enterotoxigenic Escherichia coli: 
results of a large-scale field trial. J Wect Dis, 1988. 158(2): p. 372-7. 
142. Clemens, J.D., et al ., Impact of B subunit killed whole-cell and killed whole-cell-only oral 
vaccines against cholera upon treated diarrhoeal illness and mortality in an area endemic 
for cholera. Lancet, 1988. 1(8599): p. 1375-9. 
143. Sanchez, J.L., et a!., Protective efficacy of oral whole-ceillrecombinam-B-subunit cholera 
vaccine in Pentvian military recruits. Lancet, 1994. 344(8932): p. 1273-6. 
144. Taylor, D.N., et al., Two-year study of the protective efficacy of the oral whole cell plus 
recombinant B subunit cholera vaccine in Pent. J Infect Dis, 2000. 181(5): p. 1667-73 . 
145. Clemens, J.D., D.A. Sack, and B. Ivano£( Misleading negative findings in afield trial of 
killed, oral cholera vaccine ill Pent. J Infect Dis, 2001 . 183(8): p. 1306-9. 
74 I P age 
148. Horowitz, B. , et aI., WHO Expert Commiltee on Biological Standardization World Health 
Organ Tech Rep Ser, 2004. 924: p. 1-232, backcover. 
149. Anh, D.O., et aI ., Safety and immullogenicity of a reformulated Vietnamese bivalent killed, 
whole-cell, oral cholera vaccine in adulls. Vaccine, 2007. 25(6): p. 1149-55. 
150. Tacket, C.O., et aI ., Randomized, dmlble-blind, placebo-controlled, multicentered trial of 
the efficacy of a single dose of live oral cholera vaccine CVD l03-HgR in preventing 
cholera following challenge with Vibrio cholerae 01 EI tor inaba three months after 
vaccination. Infect Immun, 1999. 67(12): p. 6341-5. 
151. Kaper ill, I.C., Attenuated Vibrio cholerae strains as live oral cholera vaccines and 
vectors. In: Levine MM. New generation vaccines, 4th ed. New York: Marcel Dekker, 
2004. 
152. Richie, E.E., et aI., Efficacy trial of single-dose live oral cholera vaccine CVD l03-HgR in 
North Jakarta, Indonesia, a cholera-endemic area. Vaccine, 2000. 18(22): p. 2399-410. 
153. Garcia, L. , et aI ., The vaccine candidate Vibrio cholerae 638 is protective against cholera 
in heallhy volunteers. Infect Immun, 2005 . 73(5): p. 3018-24. 
154. Liang, W., et aI., Constmction and evaluation of a safe, live, oral Vibrio cholerae vaccine 
candidate,IEM108. Infect Immun, 2003 . 71(10): p. 5498-504. 
155. Yan, M., et aI., A Vibrio cholerae serogroup 01 vaccine candidate against CTX ET Phi 
infection Vaccine, 2007. 25(20): p. 4046-55. 
156. Mahalanabis, D., et aI., Randomized placebo controlled human volunteer trial of a live 
oral cholera vaccine VA1.3 for safety alld immune response. Vaccine, 2009. 27(35): p. 
4850-6. 
157. Coster, I.S., et aI ., Safety, immullogellicity, and efficacy of live altellllated Vibrio cholerae 
0139 vaccine prototype. Lancet, 1995. 345(8955): p. 949-52. 
158. Tacket, C.O., et aI., Initial clinical studies of CVD 112 Vibrio cholerae 0139 live oral 
vaccine: safety and efficacy against experimental challenge. J Infect Dis, 1995. 172(3): p. 
883-6. 
159. WHO., Oral cholera vaccine use in comples emergencies: what next? . WHO meeting, 
14-16 December 2005,Cairo, Egypt. . In ., 16 December 2005. 
751 Page 
162. Crotty, S., et aI. , Culling edge: long-term tJ cell memory IfI rrufflu"" Ul'~1 ~IIIU"I/uA. 
vaccination. J Immunol, 2003 . 171(10): p. 4969-73 . 
163 . Leung, D.T., et aI. , Comparison of memory B cell, antibody-secreting cell, and plasma 
antibody responses in young children, older children, and adults with infection caused by 
Vibrio cholerae OJ El Tor Ogawa in Bangladesh. Clin Vaccine Immunol, 2011. 18(8): p. 
1317-25. 
164. Harris, A.M., Bhuiyan, M.S., Chowdhury, F. , Khan, A.I., Hossain, A. , Kendall, E.A., 
Rahman, A., LaRocque, R.C., Wrammert, J. , Ryan, E.T., Qadri, F., Calderwood, S.B. and 
Harris, J.B. , Antigen-specific memory B-cell responses to Vibrio cholerae OJ infection in 
Bangladesh. . Infect lrnmun 2009. 77, 3850-6. 
165. Durie, F.H., et aI. , The role of CD40 in the regulation of humoral and cell-mediated 
immunity. Immunol Today, 1994. 15(9): p. 406-11. 
166. Galli, S.1., et a1., Mast cells as "tunable" effector and immunoregulatory cells: recent 
advances. Annu Rev lmmunol, 2005 . 23: p. 749-86. 
167. Clemens, J.D., Sack, D.A., Harris, J.R. , Van Loon, F. , Chakraborty, 1., Ahmed, F., Rao, 
M.R., Khan, M.R. , Yunus, M., Huda, N. and et a1., Field trial of oral cholera vaccines in 
Bangladesh: results from three-year follow-up . . Lancet 1990. 335, 270-3. 
76 I P age 
